Page last updated: 2024-10-27

fluorouracil and Peripheral Nervous System Diseases

fluorouracil has been researched along with Peripheral Nervous System Diseases in 130 studies

Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.

Peripheral Nervous System Diseases: Diseases of the peripheral nerves external to the brain and spinal cord, which includes diseases of the nerve roots, ganglia, plexi, autonomic nerves, sensory nerves, and motor nerves.

Research Excerpts

ExcerptRelevanceReference
"The study investigated the potential prophylactic effect of L-carnosine against acute oxaliplatin neurotoxicity in colorectal cancer patients with emphasis on the redox (Nrf-2, MDA), inflammatory (NF-κB, TNF-α), and apoptotic (caspase-3) parameters."9.30L-Carnosine protects against Oxaliplatin-induced peripheral neuropathy in colorectal cancer patients: A perspective on targeting Nrf-2 and NF-κB pathways. ( El Abhar, H; Saad, AS; Saleh, S; Schaalan, M; Yehia, R, 2019)
"Metformin may be a promising drug in protecting colorectal cancer patients against oxaliplatin-induced chronic peripheral sensory neuropathy."9.27Role of metformin in oxaliplatin-induced peripheral neuropathy in patients with stage III colorectal cancer: randomized, controlled study. ( El-Fatatry, BM; Hussien, FZ; Ibrahim, OM; Mostafa, TM, 2018)
"Ixabepilone plus capecitabine demonstrated a clear activity and an acceptable safety profile in Chinese patients with anthracycline-pretreated/resistant and taxane-resistant metastatic breast cancer, and the majority of patients completed 6 cycles of the therapy with manageable neuropathy toxicities."9.14Ixabepilone plus capecitabine for Chinese patients with metastatic breast cancer progressing after anthracycline and taxane treatment. ( Fan, Y; Wang, J; Xu, B, 2010)
"The addition of capecitabine to docetaxel significantly improves overall survival in anthracycline-pretreated metastatic breast cancer."9.14Low-dose capecitabine plus docetaxel as first-line therapy for metastatic breast cancer: phase II results. ( Gennatas, K; Gennatas, S; Michalaki, V, 2009)
"We sought to determine whether the combination of ixabepilone plus capecitabine improved overall survival (OS) compared with capecitabine alone in patients with metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes."9.14Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. ( Conte, P; Da Costa, SC; Manikhas, A; Medina, C; Peck, R; Perez Manga, G; Poulart, V; Rixe, O; Ro, J; Rondinon, M; Rubio, G; Sparano, JA; Vrdoljak, E; Xu, B, 2010)
" This phase I/II trial was carried out to evaluate the combination of capecitabine and the proteasome inhibitor bortezomib in anthracycline and/or taxane-pretreated patients with metastatic breast cancer."9.13A phase I/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines. ( Brossart, P; Freier, W; Greil, R; Kiewe, P; Kühnhardt, D; Kümmel, S; Lange, W; Lehenbauer-Dehm, S; Niederle, N; Possinger, K; Preiss, J; Regierer, A; Schippinger, W; Schmid, P; Van de Velde, H, 2008)
"COX-2 activation may mediate capecitabine induced toxicities, eg, hand-foot syndrome (HFS) and colorectal cancer progression, both of which may be improved by concurrent celecoxib."9.12Retrospective study of capecitabine and celecoxib in metastatic colorectal cancer: potential benefits and COX-2 as the common mediator in pain, toxicities and survival? ( Ayers, GD; Brown, T; Crane, CC; Curley, SA; Delcos, M; Feig, B; Janjan, N; Lin, EH; Morris, J; Rodriguez-Bigas, MA; Ross, A; Skibber, J; Vadhan, SR, 2006)
"This study evaluated the toxicity and efficacy of docetaxel/capecitabine as neoadjuvant treatment for stage 2/3 breast cancer."9.11A phase II trial of neoadjuvant docetaxel and capecitabine for locally advanced breast cancer. ( Berman, A; Chow, CK; Danforth, D; Eng-Wong, J; Lebowitz, PF; Liu, E; Merino, MJ; Swain, SM; Venzon, D; Zia, F; Zujewski, J, 2004)
"The effectiveness of capecitabine, an oral fluoropyrimidine carbamate, is well documented in previously untreated metastatic colorectal cancer patients (overall response rate: 25%)."9.11Single-agent capecitabine in patients with metastatic colorectal cancer refractory to 5-fluorouracil/leucovorin chemotherapy. ( Bang, YJ; Heo, DS; Joh, YH; Kim, DW; Kim, NK; Kim, TM; Kim, TY; Kwon, JH; Lee, JJ; Oh, DY; Yu, SJ, 2004)
"FOLFOX, a bimonthly combination of leucovorin, 5-fluorouracil and oxaliplatin, is active in metastatic colorectal cancer, but sometimes causes cumulative sensory neurotoxicity."9.11Oxaliplatin reintroduction in patients previously treated with leucovorin, fluorouracil and oxaliplatin for metastatic colorectal cancer. ( André, T; Artru, P; Carola, E; de Gramont, A; Louvet, C; Mabro, M; Maindrault-Goebel, F; Tournigand, C, 2004)
"Docetaxel and capecitabine, a tumor-activated oral fluoropyrimidine, show high single-agent efficacy in metastatic breast cancer (MBC) and synergy in preclinical studies."9.10Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. ( Ayoub, JP; Cervantes, G; Fumoleau, P; Jones, S; Leonard, R; Lui, WY; Mauriac, L; Miles, D; Moiseyenko, V; O'Shaughnessy, J; Twelves, C; Van Hazel, G; Verma, S; Vukelja, S, 2002)
"Oral capecitabine was evaluated in terms of overall response rate, safety, and tolerability as first-line therapy in women aged > or = 55 years with advanced/metastatic breast cancer."9.09Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. ( Bell, D; Blum, J; Burger, HU; Jones, SE; Laws, S; Mauriac, L; Miles, D; Moiseyenko, V; Oshaughnessy, JA; Osterwalder, B; Rosso, R, 2001)
"To identify the maximum tolerated dose (MTD) and dose limiting toxicities (DLT) of oxaliplatin (L-OHP) given on a weekly schedule including fixed doses of leucovorin (LV) and infusional 5-fluorouracil (5-FU), to define the toxicity profile of this regimen and to find preliminary evidence of its activity in pretreated patients with metastatic colorectal cancer (MCRC)."9.09Phase I study of a weekly schedule of oxaliplatin, high-dose leucovorin, and infusional fluorouracil in pretreated patients with advanced colorectal cancer. ( Manzione, L; Pizza, C; Rosati, G; Rossi, A; Tucci, A, 2001)
"A 66-year-old woman with metastatic mammary carcinoma, who was being treated with capecitabine, contracted a herpes zoster infection that was treated with the antiviral drug brivudin."8.86Interaction between capecitabine and brivudin in a patient with breast cancer. ( Baena-Cañada, JM; García-Olmedo, O; Jiménez-Bárcenas, R; Martínez, MJ; Muriel-Cueto, P, 2010)
" Ixabepilone is approved by the FDA for treatment of patients with metastatic breast cancer (MBC) progressing after taxanes and anthracyclines, either in combination with capecitabine or as monotherapy if the patient has already progressed on capecitabine."8.86Optimizing ixabepilone treatment schedules in patients with advanced or metastatic breast cancer. ( Egerton, N, 2010)
"To review available data and implications for nurses of combination regimens containing capecitabine for metastatic breast cancer."8.85Capecitabine-based combination therapy for breast cancer: implications for nurses. ( Frye, DK, 2009)
"This article reviews the preclinical and clinical data on ixabepilone in patients with locally advanced and metastatic breast cancer (MBC) and provides guidance for pharmacists on its optimal use."8.85The optimal therapeutic use of ixabepilone in patients with locally advanced or metastatic breast cancer. ( Boehnke Michaud, L, 2009)
"The combination of capecitabine (Xeloda) and oxaliplatin (Eloxatin), or XELOX, is an effective and safe approach to the treatment of advanced colorectal cancer, with the potential advantage of convenience over standard combination regimens."8.81Can capecitabine replace 5-FU/leucovorin in combination with oxaliplatin for the treatment of advanced colorectal cancer? ( Twelves, C, 2002)
"When the 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) chemotherapy regimen is used to treat colorectal cancer (CRC), chemotherapy-induced peripheral neuropathy (CIPN) caused by oxaliplatin can substantially affect quality of life (QOL) in the CRC patients."7.96Emotional distress and quality of life during folinic acid, fluorouracil, and oxaliplatin in colorectal cancer patients with and without chemotherapy-induced peripheral neuropathy: A cross-sectional study. ( Chen, JL; Chou, PL; Hsu, HT; Huang, YY; Juan, CH; Lin, PC; Wu, LM, 2020)
" For practical reasons and for the convenience of the patient, we used XELOX (Xeloda 2000 mg/m2 orally on days 1-14 and oxaliplatin 130 mg/m2 as a 30-min infusion on day 1) in patients with advanced colorectal cancer resistant to irinotecan and 5-fluorouracil."7.72Short-time infusion of oxaliplatin (Eloxatin) in combination with capecitabine (Xeloda) in patients with advanced colorectal cancer. ( Hahn, P; Jensen, HA; Pfeiffer, P, 2003)
" We undertook a retrospective study comparing the incidences of hand-foot syndrome in 67 patients with metastatic colorectal cancer who took capecitabine (Xeloda) with or without celecoxib."7.71Effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity. ( Ayers, GD; Lin, E; Morris, JS, 2002)
" Severe taxane-related toxic effects were more frequent in group A, while severe thrombocytopenia was low and present only in group A."6.73Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00. ( Bafaloukos, D; Briasoulis, E; Dafni, U; Dimitrakakis, K; Dimopoulos, AM; Fountzilas, G; Gogas, H; Kalofonos, HP; Karanikiotis, C; Karina, M; Linardou, H; Makrantonakis, P; Markopoulos, C; Papadimitriou, C; Papakostas, P; Pectasides, D; Pisanidis, N; Polichronis, A; Samantas, E; Skarlos, D; Stathopoulos, GP; Tzorakoeleftherakis, E; Varthalitis, I; Xiros, N, 2008)
"Patients with colorectal cancer (CRC) and liver metastases have a poor prognosis, but can benefit from perioperative chemotherapy and disease resection."6.73Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. ( Gruenberger, B; Gruenberger, T; Herbst, F; Scheithauer, W; Schueller, J; Tamandl, D; Zielinski, C, 2008)
" We weekly applied the orofacial section of the Acute and Chronic Neuropathy Questionnaire of Common Toxicity Criteria for Adverse Events of the National Cancer Institute of the United States of America (Oxaliplatin-specific neurotoxicity scale)."5.56FLOX (5-fluorouracil + leucovorin + oxaliplatin) chemotherapy for colorectal cancer leads to long-term orofacial neurotoxicity: a STROBE-guided longitudinal prospective study. ( Costa, BA; da Rocha Filho, DR; de Albuquerque Ribeiro Gondinho, P; de Barros Silva, PG; Gifoni, MAC; Junior, RCPL; Lima, MVA; Lisboa, MRP; Vale, ML, 2020)
"Platinum was readily detectable in skin biopsies more than 60 months post-completion of FOLFOX."5.51Skin platinum deposition in colorectal cancer patients following oxaliplatin-based therapy. ( Cao, Y; Chang, Q; Chen, EX; Hedley, D; Ornatsky, O; Zhang, W, 2019)
"Twenty-eight colorectal cancer patients who received infusional 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) therapy were randomly and evenly assigned to the cystine and theanine group and the control group."5.34Protective effect of the oral administration of cystine and theanine on oxaliplatin-induced peripheral neuropathy: a pilot randomized trial. ( Abe, T; Akazawa, N; Hirashima, T; Ichikawa, H; Kakita, T; Kobayashi, M; Komura, T; Oikawa, M; Okada, T; Otake, S; Sato, R; Tsuchiya, T; Yazawa, T, 2020)
"Fluorouracil (5-FU), leucovorin (LV) and oxaliplatin (FOLFOX) plus panitumumab therapy is a commonly used first-line chemotherapy for metastatic colorectal cancer (mCRC)."5.30SAPPHIRE: a randomised phase II study of planned discontinuation or continuous treatment of oxaliplatin after six cycles of modified FOLFOX6 plus panitumumab in patients with colorectal cancer. ( Fukunaga, M; Kato, T; Kotaka, M; Kuramochi, H; Kuroda, H; Kurosawa, S; Minagawa, N; Mishima, H; Miura, T; Miwa, K; Munemoto, Y; Nagata, N; Nakamura, M; Noura, S; Oba, K; Sakamoto, J; Satake, H; Takahashi, M; Takahashi, T; Touyama, T, 2019)
"The study investigated the potential prophylactic effect of L-carnosine against acute oxaliplatin neurotoxicity in colorectal cancer patients with emphasis on the redox (Nrf-2, MDA), inflammatory (NF-κB, TNF-α), and apoptotic (caspase-3) parameters."5.30L-Carnosine protects against Oxaliplatin-induced peripheral neuropathy in colorectal cancer patients: A perspective on targeting Nrf-2 and NF-κB pathways. ( El Abhar, H; Saad, AS; Saleh, S; Schaalan, M; Yehia, R, 2019)
"Metformin may be a promising drug in protecting colorectal cancer patients against oxaliplatin-induced chronic peripheral sensory neuropathy."5.27Role of metformin in oxaliplatin-induced peripheral neuropathy in patients with stage III colorectal cancer: randomized, controlled study. ( El-Fatatry, BM; Hussien, FZ; Ibrahim, OM; Mostafa, TM, 2018)
" Patients aged 18 years or older with high-risk stage II and stage III colorectal cancer underwent central randomisation with minimisation for centre, choice of regimen, sex, disease site, N stage, T stage, and the starting dose of capecitabine."5.273 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial. ( Allan, K; Azzabi, A; Boyd, KA; Bridgewater, J; Briggs, A; Cassidy, J; Cunningham, D; Dhadda, AS; Ellis, R; Essapen, S; Falk, S; Farrugia, D; Glimelius, B; Gollins, S; Harkin, A; Harrison, M; Haydon, A; Hickish, T; Hollander, NH; Iveson, TJ; Kerr, RS; McQueen, J; Medley, L; Olesen, RK; Paul, J; Propper, D; Raouf, S; Rees, C; Saunders, MP; Scudder, C; Tabernero, J; Wasan, HS; Waterston, A; Weaver, A; Webb, A; Wilson, C, 2018)
" We therefore conducted a multicenter randomized phase III trial to compare fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) with and without Goshajinkigan (GJG), a traditional Japanese herbal medicine (Kampo), to determine GJG's potential for reducing peripheral neuropathy in patients with colorectal cancer."5.20Preventive effect of Goshajinkigan on peripheral neurotoxicity of FOLFOX therapy (GENIUS trial): a placebo-controlled, double-blind, randomized phase III study. ( Baba, H; Emi, Y; Higashijima, J; Ishida, H; Kakeji, Y; Kato, T; Kojima, H; Kon, M; Kono, T; Maehara, Y; Miyake, Y; Ogata, Y; Oki, E; Saeki, H; Sakaguchi, Y; Shirabe, K; Takahashi, K; Tomita, N; Yamanaka, T, 2015)
"Infusional 5-fluorouracil and leucovorin with oxaliplatin is one of the standard regimens for patients with pretreated metastatic colorectal cancer, as well as for first-line chemotherapy."5.15A multicenter phase-II study of 5-FU, leucovorin and oxaliplatin (FOLFOX6) in patients with pretreated metastatic colorectal cancer. ( Esaki, T; Fujii, H; Inaba, Y; Kato, K; Kusaba, H; Mizuno, T; Mizunuma, N; Muro, K; Shimada, Y; Shirao, K; Tsuji, Y; Yoshioka, A, 2011)
"The addition of capecitabine to docetaxel significantly improves overall survival in anthracycline-pretreated metastatic breast cancer."5.14Low-dose capecitabine plus docetaxel as first-line therapy for metastatic breast cancer: phase II results. ( Gennatas, K; Gennatas, S; Michalaki, V, 2009)
"Oxaliplatin is a promising drug for cancer therapy and the oxaliplatin/5-fluorouracil/leucovorin (FOLFOX) regimen has become the standard adjuvant treatment for colorectal cancer."5.14Administration of reduced glutathione in FOLFOX4 adjuvant treatment for colorectal cancer: effect on oxaliplatin pharmacokinetics, Pt-DNA adduct formation, and neurotoxicity. ( Airoldi, M; Cattel, L; Drescher, A; Jaehde, U; Milla, P; Weber, G, 2009)
"We sought to determine whether the combination of ixabepilone plus capecitabine improved overall survival (OS) compared with capecitabine alone in patients with metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes."5.14Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. ( Conte, P; Da Costa, SC; Manikhas, A; Medina, C; Peck, R; Perez Manga, G; Poulart, V; Rixe, O; Ro, J; Rondinon, M; Rubio, G; Sparano, JA; Vrdoljak, E; Xu, B, 2010)
"Ixabepilone plus capecitabine demonstrated a clear activity and an acceptable safety profile in Chinese patients with anthracycline-pretreated/resistant and taxane-resistant metastatic breast cancer, and the majority of patients completed 6 cycles of the therapy with manageable neuropathy toxicities."5.14Ixabepilone plus capecitabine for Chinese patients with metastatic breast cancer progressing after anthracycline and taxane treatment. ( Fan, Y; Wang, J; Xu, B, 2010)
" This phase I/II trial was carried out to evaluate the combination of capecitabine and the proteasome inhibitor bortezomib in anthracycline and/or taxane-pretreated patients with metastatic breast cancer."5.13A phase I/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines. ( Brossart, P; Freier, W; Greil, R; Kiewe, P; Kühnhardt, D; Kümmel, S; Lange, W; Lehenbauer-Dehm, S; Niederle, N; Possinger, K; Preiss, J; Regierer, A; Schippinger, W; Schmid, P; Van de Velde, H, 2008)
"COX-2 activation may mediate capecitabine induced toxicities, eg, hand-foot syndrome (HFS) and colorectal cancer progression, both of which may be improved by concurrent celecoxib."5.12Retrospective study of capecitabine and celecoxib in metastatic colorectal cancer: potential benefits and COX-2 as the common mediator in pain, toxicities and survival? ( Ayers, GD; Brown, T; Crane, CC; Curley, SA; Delcos, M; Feig, B; Janjan, N; Lin, EH; Morris, J; Rodriguez-Bigas, MA; Ross, A; Skibber, J; Vadhan, SR, 2006)
"This study evaluated the toxicity and efficacy of docetaxel/capecitabine as neoadjuvant treatment for stage 2/3 breast cancer."5.11A phase II trial of neoadjuvant docetaxel and capecitabine for locally advanced breast cancer. ( Berman, A; Chow, CK; Danforth, D; Eng-Wong, J; Lebowitz, PF; Liu, E; Merino, MJ; Swain, SM; Venzon, D; Zia, F; Zujewski, J, 2004)
"FOLFOX, a bimonthly combination of leucovorin, 5-fluorouracil and oxaliplatin, is active in metastatic colorectal cancer, but sometimes causes cumulative sensory neurotoxicity."5.11Oxaliplatin reintroduction in patients previously treated with leucovorin, fluorouracil and oxaliplatin for metastatic colorectal cancer. ( André, T; Artru, P; Carola, E; de Gramont, A; Louvet, C; Mabro, M; Maindrault-Goebel, F; Tournigand, C, 2004)
"The effectiveness of capecitabine, an oral fluoropyrimidine carbamate, is well documented in previously untreated metastatic colorectal cancer patients (overall response rate: 25%)."5.11Single-agent capecitabine in patients with metastatic colorectal cancer refractory to 5-fluorouracil/leucovorin chemotherapy. ( Bang, YJ; Heo, DS; Joh, YH; Kim, DW; Kim, NK; Kim, TM; Kim, TY; Kwon, JH; Lee, JJ; Oh, DY; Yu, SJ, 2004)
"Docetaxel and capecitabine, a tumor-activated oral fluoropyrimidine, show high single-agent efficacy in metastatic breast cancer (MBC) and synergy in preclinical studies."5.10Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. ( Ayoub, JP; Cervantes, G; Fumoleau, P; Jones, S; Leonard, R; Lui, WY; Mauriac, L; Miles, D; Moiseyenko, V; O'Shaughnessy, J; Twelves, C; Van Hazel, G; Verma, S; Vukelja, S, 2002)
"Diarrhea is dose-limiting with weekly 5-fluorouracil (5-FU) plus high-dose leucovorin (LV)."5.09Phase I and pharmacokinetic study of weekly 5-fluorouracil administered with granulocyte-macrophage colony-stimulating factor and high-dose leucovorin: a potential role for growth factor as mucosal protectant. ( Blumenson, LE; Creaven, PJ; Frank, C; Meropol, NJ; Rustum, YM, 1999)
"Oral capecitabine was evaluated in terms of overall response rate, safety, and tolerability as first-line therapy in women aged > or = 55 years with advanced/metastatic breast cancer."5.09Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. ( Bell, D; Blum, J; Burger, HU; Jones, SE; Laws, S; Mauriac, L; Miles, D; Moiseyenko, V; Oshaughnessy, JA; Osterwalder, B; Rosso, R, 2001)
"To identify the maximum tolerated dose (MTD) and dose limiting toxicities (DLT) of oxaliplatin (L-OHP) given on a weekly schedule including fixed doses of leucovorin (LV) and infusional 5-fluorouracil (5-FU), to define the toxicity profile of this regimen and to find preliminary evidence of its activity in pretreated patients with metastatic colorectal cancer (MCRC)."5.09Phase I study of a weekly schedule of oxaliplatin, high-dose leucovorin, and infusional fluorouracil in pretreated patients with advanced colorectal cancer. ( Manzione, L; Pizza, C; Rosati, G; Rossi, A; Tucci, A, 2001)
" All included patients who were treated for colorectal cancer, mainly with oxaliplatin in combination with 5-fluorouracil/leucovorin."4.90A systematic review on chronic oxaliplatin-induced peripheral neuropathy and the relation with oxaliplatin administration. ( Beijers, AJ; Mols, F; Vreugdenhil, G, 2014)
" Ixabepilone is approved by the FDA for treatment of patients with metastatic breast cancer (MBC) progressing after taxanes and anthracyclines, either in combination with capecitabine or as monotherapy if the patient has already progressed on capecitabine."4.86Optimizing ixabepilone treatment schedules in patients with advanced or metastatic breast cancer. ( Egerton, N, 2010)
"A 66-year-old woman with metastatic mammary carcinoma, who was being treated with capecitabine, contracted a herpes zoster infection that was treated with the antiviral drug brivudin."4.86Interaction between capecitabine and brivudin in a patient with breast cancer. ( Baena-Cañada, JM; García-Olmedo, O; Jiménez-Bárcenas, R; Martínez, MJ; Muriel-Cueto, P, 2010)
"This article reviews the preclinical and clinical data on ixabepilone in patients with locally advanced and metastatic breast cancer (MBC) and provides guidance for pharmacists on its optimal use."4.85The optimal therapeutic use of ixabepilone in patients with locally advanced or metastatic breast cancer. ( Boehnke Michaud, L, 2009)
"To review available data and implications for nurses of combination regimens containing capecitabine for metastatic breast cancer."4.85Capecitabine-based combination therapy for breast cancer: implications for nurses. ( Frye, DK, 2009)
"The combination of capecitabine (Xeloda) and oxaliplatin (Eloxatin), or XELOX, is an effective and safe approach to the treatment of advanced colorectal cancer, with the potential advantage of convenience over standard combination regimens."4.81Can capecitabine replace 5-FU/leucovorin in combination with oxaliplatin for the treatment of advanced colorectal cancer? ( Twelves, C, 2002)
"When the 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) chemotherapy regimen is used to treat colorectal cancer (CRC), chemotherapy-induced peripheral neuropathy (CIPN) caused by oxaliplatin can substantially affect quality of life (QOL) in the CRC patients."3.96Emotional distress and quality of life during folinic acid, fluorouracil, and oxaliplatin in colorectal cancer patients with and without chemotherapy-induced peripheral neuropathy: A cross-sectional study. ( Chen, JL; Chou, PL; Hsu, HT; Huang, YY; Juan, CH; Lin, PC; Wu, LM, 2020)
"Oxaliplatin, combined with capecitabine (CAPOX) or infused 5-fluorouracil (FOLFOX), is standard of care in the adjuvant treatment of colorectal cancer (CRC)."3.91Long-term neuropathy and quality of life in colorectal cancer patients treated with oxaliplatin containing adjuvant chemotherapy. ( Bono, P; Hänninen, UA; Karhunen, M; Lamminmäki, A; Osterlund, P; Soveri, LM, 2019)
"Oxaliplatin in combination with infusional 5-fluorouracil/leucovorin (FOLFOX) have emerged as the standard of care in the therapy of advanced-stage colorectal cancer."3.74[Reduction of oxaliplatin-related neurotoxicity by calcium and magnesium infusions]. ( Akashi, T; Ando, H; Hanaoka, T; Itagaki, H; Kobayashi, Y; Muto, O; Ono, T; Onuki, M; Tanaka, Y, 2007)
"Oxaliplatin in combination with infusional 5-fluorouracil/Leucovorin (FOLFOX) has emerged as the treatment of choice for advanced-stage colorectal cancer."3.74[Reduction of oxaliplatin-related neurotoxicity by Gosha-jinki-gan]. ( Hibino, M; Imano, H; Nakamura, M; Shindo, Y; Tenma, K; Yoshino, K, 2008)
" For practical reasons and for the convenience of the patient, we used XELOX (Xeloda 2000 mg/m2 orally on days 1-14 and oxaliplatin 130 mg/m2 as a 30-min infusion on day 1) in patients with advanced colorectal cancer resistant to irinotecan and 5-fluorouracil."3.72Short-time infusion of oxaliplatin (Eloxatin) in combination with capecitabine (Xeloda) in patients with advanced colorectal cancer. ( Hahn, P; Jensen, HA; Pfeiffer, P, 2003)
" We undertook a retrospective study comparing the incidences of hand-foot syndrome in 67 patients with metastatic colorectal cancer who took capecitabine (Xeloda) with or without celecoxib."3.71Effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity. ( Ayers, GD; Lin, E; Morris, JS, 2002)
" This prospective cohort study investigated orofacial complications of combination chemotherapy (cyclophosphamide, methotrexate, fluorouracil, vincristine, and prednisone) in women with breast cancer."3.68Orofacial complications of chemotherapy for breast cancer. ( McCarthy, GM; Skillings, JR, 1992)
"Chemotherapy in relapsed colorectal cancer patients treated with oxaliplatin as adjuvant chemotherapy is under debate."2.94Evaluation of FOLFOX or CAPOX reintroduction with or without bevacizumab in relapsed colorectal cancer patients treated with oxaliplatin as adjuvant chemotherapy (REACT study). ( Fukunaga, M; Ide, Y; Ikumoto, T; Iwamoto, S; Kanazawa, A; Kato, T; Konishi, K; Kotaka, M; Kudo, T; Kurata, T; Sakai, D; Sano, Y; Satake, H; Satoh, T; Sugimoto, N; Tomita, N; Tsuji, A; Yamanaka, T, 2020)
" The secondary endpoints were chronic cumulative neurotoxicity (EORTC QLQ-CIPN20), time to grade 2 neurotoxicity (NCI-CTCAE or the oxaliplatin-specific neuropathy scale), acute neurotoxicity (analog scale), rates of dose reduction or withdrawal due to OIPN, 3-year disease-free survival (DFS) and adverse events."2.94Phase III randomized, placebo-controlled, double-blind study of monosialotetrahexosylganglioside for the prevention of oxaliplatin-induced peripheral neurotoxicity in stage II/III colorectal cancer. ( Chen, G; Deng, YH; Ding, PR; Fan, WH; Feng, F; Jin, Y; Li, YH; Liang, HL; Lu, ZH; Peng, JW; Ren, C; Shi, SM; Wang, DS; Wang, F; Wang, FH; Wang, W; Wang, ZQ; Xie, CB; Xu, RH; Zhang, JW, 2020)
"There were no statistically significant neuropathy differences among the study arms as measured by the primary end point or additional measures of neuropathy, including clinician-determined measurement of the time to grade 2 neuropathy by using the National Cancer Institute Common Terminology Criteria for Adverse Events scale or an oxaliplatin-specific neuropathy scale."2.79Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance). ( Atherton, P; Dakhil, SR; Fehrenbacher, L; Flynn, KA; Grothey, A; Lewis, GC; Loprinzi, CL; Qamar, R; Qin, R; Seisler, D, 2014)
"To establish a safe regimen of high-dose regional chemotherapy with NIPP using cisplatin in patients with incurable rectal cancer."2.79Negative-balance isolated pelvic perfusion in patients with incurable symptomatic rectal cancer: results and drug dose correlation to adverse events. ( Kim, C; Kimata, R; Kumita, S; Murata, S; Onozawa, S; Tajima, H; Uchida, E, 2014)
" The severity of OPN was assessed according to the Common Toxicity Criteria for Adverse Events at baseline, every 2 weeks until the 8th cycle, and every 4 weeks thereafter until the 26th week."2.78Goshajinkigan oxaliplatin neurotoxicity evaluation (GONE): a phase 2, multicenter, randomized, double‑blind, placebo‑controlled trial of goshajinkigan to prevent oxaliplatin‑induced neuropathy. ( Fukunaga, M; Hata, T; Kojima, H; Kono, T; Matsui, T; Mishima, H; Morita, S; Munemoto, Y; Nagata, N; Sakamoto, J; Shimada, M; Takemoto, H, 2013)
" This study was to investigate the efficacy and safety of oxaliplatin in combination with capecitabine as first-line chemotherapy for AGC patients."2.74[Oxaliplatin combined with capecitabine as first-line chemotherapy for patients with advanced gastric cancer]. ( Dong, NN; Liu, ZF; Wang, MY; Zhang, Q, 2009)
"The aim of the study was to assess the toxicity and the clinical activity of biweekly oxaliplatin (OXA) in combination with continuous infusional 5-fluorouracil (5-FU) and leucovorin (LV) administered every 2 weeks (modified FOLFOX-4 regimen) in elderly patients with advanced gastric cancer (AGC)."2.73Biweekly oxaliplatin in combination with continuous infusional 5-fluorouracil and leucovorin (modified FOLFOX-4 regimen) as first-line chemotherapy for elderly patients with advanced gastric cancer. ( Fu, Z; Guan, F; Guo, QS; Liu, ZF; Wang, MY; Yang, XG; Zhang, XQ, 2008)
" Severe taxane-related toxic effects were more frequent in group A, while severe thrombocytopenia was low and present only in group A."2.73Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00. ( Bafaloukos, D; Briasoulis, E; Dafni, U; Dimitrakakis, K; Dimopoulos, AM; Fountzilas, G; Gogas, H; Kalofonos, HP; Karanikiotis, C; Karina, M; Linardou, H; Makrantonakis, P; Markopoulos, C; Papadimitriou, C; Papakostas, P; Pectasides, D; Pisanidis, N; Polichronis, A; Samantas, E; Skarlos, D; Stathopoulos, GP; Tzorakoeleftherakis, E; Varthalitis, I; Xiros, N, 2008)
"Patients with colorectal cancer (CRC) and liver metastases have a poor prognosis, but can benefit from perioperative chemotherapy and disease resection."2.73Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. ( Gruenberger, B; Gruenberger, T; Herbst, F; Scheithauer, W; Schueller, J; Tamandl, D; Zielinski, C, 2008)
"Neurotoxicity was recorded for all patients using standard adverse event reporting."2.73Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07. ( Bearden, JD; Cecchini, RS; Cella, D; Colangelo, LH; Colman, LK; Costantino, JP; Ganz, PA; Kopec, JA; Kuebler, JP; Land, SR; Lanier, KS; Murphy, K; Needles, BM; O'Connell, MJ; Pajon, ER; Seay, TE; Smith, RE; Wieand, HS; Wolmark, N, 2007)
" Pharmacokinetic and neurotoxicity assessments were performed at the cohort 2 MTD."2.71Phase I and pharmacokinetic study of two different schedules of oxaliplatin, irinotecan, Fluorouracil, and leucovorin in patients with solid tumors. ( Adjei, AA; Ames, MM; Atherton, P; Erlichman, C; Galanis, E; Goetz, MP; Goldberg, RM; Pitot, H; Reid, JM; Rubin, J; Sloan, JA; Windebank, AJ, 2003)
" In 10 of 19 patients who had not responded (SD, PD), three additional courses of chemotherapy were combined with sCMT (with 25 sCMT applications)."2.71Whole-body hyperthermia in the scope of von Ardenne's systemic cancer multistep therapy (sCMT) combined with chemotherapy in patients with metastatic colorectal cancer: a phase I/II study. ( Ahlers, O; Deja, M; Dräger, J; Felix, R; Hildebrandt, B; Kerner, T; Löffel, J; Riess, H; Stroszczynski, C; Wust, P, 2004)
"Grade 2/3 neutropenia was observed in 4 (3%) treatment cycles."2.71Dose escalation study on oxaliplatin and capecitabine (Xeloda) in patients with advanced solid tumors. ( Agelaki, S; Amarantidis, K; Androulakis, N; Georgoulias, V; Kakolyris, S; Kouroussis, C; Mavroudis, D; Samonis, G; Souglakos, J; Vardakis, N; Xenidis, N, 2004)
" Pharmacokinetic parameters of capecitabine and its metabolites (5'-deoxy-5-fluorouridine, 5-fluorouracil and alpha-fluoro-beta-alanine) were similar to those reported by other authors."2.70Phase I trial of capecitabine in combination with interferon alpha in patients with metastatic renal cancer: toxicity and pharmacokinetics. ( Budd, GT; Bukowski, R; Chang, DZ; Ganapathi, R; Olencki, T; Osterwalder, B; Peereboom, D, 2001)
"Fifty-seven Dukes C colorectal cancer patients were given 5-fluorouracil-interferon-alpha 2b adjuvant treatment from October 1986 to September 1990."2.675-Fluorouracil-interferon-alpha 2b adjuvant treatment of Dukes C colorectal cancer. ( Cremone, L; Espinosa, A; Faiella, F; Frasci, G; Leone, F; Monaco, M; Persico, G; Sapio, U, 1994)
"Patterns of breast cancer care continue to be amended because of the more frequent use of anthracyclines and taxanes in earlier lines of therapy (particularly in the adjuvant setting) and the emergence of multidrug resistance."2.46Ixabepilone. ( Stein, A, 2010)
"Oxaliplatin utilized in colorectal neoplasms treatment could induce acute peripheral neuropathy (APN) which is a dreadful and frequent adverse event."1.91Incidence and risk factors associated with development of oxalipatin-induced acute peripheral neuropathy in colorectal cancer patients. ( Ben Ayed, W; Ben Mahmoud, IT; Ben Said, A; Berguiga, S; Cherif, I; Hamdi, A; Houij, R; Limayem, I, 2023)
"The prognosis of pancreatic cancer (PC) has been improved by new chemotherapy regimens (combination of 5-fluorouracil, oxaliplatin, irinotecan, and leucovorin (FOLFIRINOX) or gemcitabine plus nab-paclitaxel (GnP))."1.62Mirogabalin vs pregabalin for chemotherapy-induced peripheral neuropathy in pancreatic cancer patients. ( Asama, H; Hashimoto, M; Hikichi, T; Irie, H; Kato, T; Kobashi, R; Konno, N; Nakamura, J; Ohira, H; Okubo, Y; Sato, Y; Sugimoto, M; Suzuki, R; Takagi, T; Takasumi, M, 2021)
"By using the Korean Pancreatic Cancer (K-PaC) registry, we compared the clinical outcomes of FOLFIRINOX (FFX) and gemcitabine plus nab-paclitaxel (GNP) in patients with metastatic pancreatic cancer (MPC)."1.56Comparison of FOLFIRINOX and Gemcitabine Plus Nab-paclitaxel for Treatment of Metastatic Pancreatic Cancer: Using Korean Pancreatic Cancer (K-PaC) Registry. ( Cha, HS; Hwang, JH; Kim, J; Kim, JW; Kim, MJ; Lee, JC; Lee, WJ; Park, P; Shin, DW; Woo, SM; Yang, SY, 2020)
" We weekly applied the orofacial section of the Acute and Chronic Neuropathy Questionnaire of Common Toxicity Criteria for Adverse Events of the National Cancer Institute of the United States of America (Oxaliplatin-specific neurotoxicity scale)."1.56FLOX (5-fluorouracil + leucovorin + oxaliplatin) chemotherapy for colorectal cancer leads to long-term orofacial neurotoxicity: a STROBE-guided longitudinal prospective study. ( Costa, BA; da Rocha Filho, DR; de Albuquerque Ribeiro Gondinho, P; de Barros Silva, PG; Gifoni, MAC; Junior, RCPL; Lima, MVA; Lisboa, MRP; Vale, ML, 2020)
"Platinum was readily detectable in skin biopsies more than 60 months post-completion of FOLFOX."1.51Skin platinum deposition in colorectal cancer patients following oxaliplatin-based therapy. ( Cao, Y; Chang, Q; Chen, EX; Hedley, D; Ornatsky, O; Zhang, W, 2019)
" Neurological adverse effects were assessed by CTC v2."1.51Effect of diabetes on neurological adverse effects and chemotherapy induced peripheral neuropathy in advanced colorectal cancer patients treated with different FOLFOX regimens. ( Bano, N; Ikram, R, 2019)
"Thirteen patients with metastatic pancreatic cancer underwent clinical, sonographic, and electrophysiological evaluation before, 3 and 7 months after treatment with 12 two-week cycles of FOLFIRINOX."1.51Prospective Study of the Clinical, Electrophysiologic, and Sonographic Characteristics of Oxaliplatin-Induced Neuropathy. ( Fisse, AL; Gold, R; Höffken, N; Lönneker, N; Pitarokoili, K; Reinacher-Schick, A; Trampe, N; Yoon, MS, 2019)
"Forty-seven cases of stage III colorectal cancer who received adjuvant chemotherapy with oxaliplatin after curative surgery between January 2010 and August 2014 were retrospectively reviewed."1.46Hyperacute peripheral neuropathy is a predictor of oxaliplatin-induced persistent peripheral neuropathy. ( Horiuchi, T; Kimura, M; Maeda, T; Shirai, Y; Tanishima, H; Tominaga, T, 2017)
" By exclusion the pseudo-obstruction was attributed to a toxic oxaliplatin-induced autonomic neuropathy which slowly improved during months of follow-up."1.42A case of delayed oxaliplatin-induced pseudo-obstruction: an atypical presentation of oxaliplatin neurotoxicity. ( Bleecker, JD; Pauwels, W; Vandamme, M, 2015)
"Participants were 91 colorectal cancer patients treated with OXA-based chemotherapy."1.40Long-term course of oxaliplatin-induced polyneuropathy: a prospective 2-year follow-up study. ( Alberti, P; Argyriou, AA; Bergamo, F; Briani, C; Bruna, J; Cacciavillani, M; Campagnolo, M; Cavaletti, G; Cazzaniga, M; Cortinovis, D; Frigeni, B; Izquierdo, C; Kalofonos, HP; Velasco, R, 2014)
"Patients with colorectal cancer who received adjuvant CAPOX from January 2005 to August 2011 were reviewed."1.40Incidence of cold-induced peripheral neuropathy and dose modification of adjuvant oxaliplatin-based chemotherapy for patients with colorectal cancer. ( Altaf, R; Kristensen, B; Lund Brixen, A; Nielsen, SE, 2014)
"We retrospectively investigated the frequency and severity of adverse events in 124 patients with colorectal cancer who were treated by mFOLFOX6 regimen from August, 2005 to December, 2006."1.35[Revision of the informed consent form for patients based on investigation of adverse events of mFOLFOX6 regimen]. ( Boku, N; Kato, T; Kimura, H; Kudou, Y; Matsunaga, Y; Motokawa, S; Muramatsu, T; Nagata, N; Nakagaki, S; Ohashi, Y; Shino, M; Yamazaki, K; Yoshida, T, 2009)
"The standard adjuvant therapy for rectal cancer is 5-fluorouracil (5-FU) often combined with radiotherapy."1.35A case of 5-fluorouracil-induced peripheral neuropathy. ( De Bleecker, JL; Pauwels, WJ; Werbrouck, BF, 2008)
"Patients who had rectal cancer with a distal margin within 6 cm of the anal verge had the anus included in the field of radiotherapy (Group A, n = 26)."1.33Preoperative chemoradiation for rectal cancer causes prolonged pudendal nerve terminal motor latency. ( Chao, MW; Gibbs, P; Hiscock, R; Lim, JF; Tjandra, JJ, 2006)
"Capecitabine (CAP) is a pro-drug of 5-FU and peripheral neuropathy associated with CAP has not been reported."1.32Peripheral neuropathy associated with capecitabine. ( Diasio, RB; McGee, PJ; Saif, MW; Wood, TE, 2004)
"Carbamazepine levels were 4."1.31[Prevention of oxaliplatin-induced neuropathy by carbamazepine. A pilot study]. ( Adelsberger, H; Eckel, F; Erdmann, J; Lersch, C; Quasthoff, S; Schmelz, R, 2002)
"Carbamazepine therapy was tried in 12 additional patients to determine whether the neurologic effects might be relieved."1.31Acute oxaliplatin-induced peripheral nerve hyperexcitability. ( Floeter, MK; Grem, JL; Lehky, T; Quinn, MG; Thomas, RR; Wilson, RH, 2002)
"For locally advanced primary colorectal cancer, our institution has combined intraoperative electron irradiation (IOERT) with external beam irradiation (EBRT) +/- 5-fluorouracil (5-FU) and surgical resection."1.30Locally advanced primary colorectal cancer: intraoperative electron and external beam irradiation +/- 5-FU. ( Cha, S; Devine, R; Dozois, R; Fieck, JM; Gunderson, LL; Haddock, M; Martenson, JA; Nelson, H; O'Connell, MJ; Wolff, B, 1997)
"Effect of this treatment on the pain could be evaluated in 16 patients."1.27Palliation of pelvic recurrence of colorectal cancer with intra-arterial 5-fluorouracil and mitomycin. ( Chuang, VP; Claghorn, L; Mavligit, G; Patt, YZ; Peters, RE; Wallace, S, 1985)

Research

Studies (130)

TimeframeStudies, this research(%)All Research%
pre-19905 (3.85)18.7374
1990's8 (6.15)18.2507
2000's47 (36.15)29.6817
2010's53 (40.77)24.3611
2020's17 (13.08)2.80

Authors

AuthorsStudies
Sugimoto, M1
Takagi, T1
Suzuki, R1
Konno, N1
Asama, H1
Sato, Y2
Irie, H1
Okubo, Y1
Nakamura, J1
Takasumi, M1
Hashimoto, M1
Kato, T8
Kobashi, R1
Hikichi, T1
Ohira, H1
Ben Mahmoud, IT1
Ben Said, A1
Berguiga, S1
Houij, R1
Cherif, I1
Hamdi, A1
Ben Ayed, W1
Limayem, I1
Yoshino, T4
Oki, E3
Misumi, T1
Kotaka, M7
Manaka, D4
Eto, T2
Hasegawa, J5
Takagane, A4
Nakamura, M4
Munemoto, Y6
Nakamura, F1
Bando, H2
Taniguchi, H2
Sakamoto, Y1
Shiozawa, M2
Nishi, M1
Horiuchi, T2
Yamagishi, H1
Sakamoto, J5
Mizushima, T3
Ohtsu, A5
Mori, M2
Okamoto, K1
Nozawa, H1
Emoto, S1
Murono, K1
Sasaki, K1
Ishihara, S1
Takahashi, M1
Kuroda, H1
Minagawa, N1
Noura, S1
Fukunaga, M3
Kuramochi, H1
Touyama, T3
Takahashi, T1
Miwa, K1
Satake, H3
Kurosawa, S1
Miura, T1
Mishima, H2
Oba, K2
Nagata, N4
Yamanaka, T3
Takeuchi, S1
Gamoh, M1
Saji, S2
Maehara, Y3
Cao, Y1
Chang, Q1
Zhang, W1
Ornatsky, O1
Hedley, D1
Chen, EX1
Shinozaki, K3
Matsui, T3
Ishigure, K2
Inoue, K1
Ishikawa, H2
Ishida, H4
Ogata, Y2
Goto, K1
Wang, DS1
Wang, ZQ1
Chen, G1
Peng, JW1
Wang, W1
Deng, YH1
Wang, FH1
Zhang, JW1
Liang, HL1
Feng, F1
Xie, CB1
Ren, C1
Jin, Y1
Shi, SM1
Fan, WH1
Lu, ZH1
Ding, PR1
Wang, F1
Xu, RH1
Li, YH1
Hsu, HT1
Wu, LM1
Lin, PC1
Juan, CH1
Huang, YY1
Chou, PL1
Chen, JL1
Tanabe, Y1
Shiraishi, S1
Hashimoto, K1
Ikeda, K1
Nishizawa, D1
Shimomura, A1
Ozaki, Y1
Tamura, N1
Yunokawa, M1
Yonemori, K1
Takano, T1
Kawabata, H1
Tamura, K1
Fujiwara, Y1
Shimizu, C1
Iwamoto, S1
Sakai, D1
Kudo, T1
Konishi, K1
Ide, Y1
Ikumoto, T1
Tsuji, A2
Sano, Y1
Sugimoto, N1
Satoh, T1
Kanazawa, A1
Kurata, T1
Tomita, N2
Park, H1
Jin, RU1
Wang-Gillam, A1
Suresh, R1
Rigden, C1
Amin, M1
Tan, BR1
Pedersen, KS1
Lim, KH1
Trikalinos, NA1
Acharya, A1
Copsey, ML1
Navo, KA1
Morton, AE1
Gao, F1
Lockhart, AC1
Mashimo, K1
Fujiwara, D1
Hoshida, T1
Morimoto, N1
Noda, A1
Takeda, T1
Tsubaki, M2
Nishida, S1
Sakaguchi, K1
Kobayashi, M2
Sato, R1
Komura, T1
Ichikawa, H1
Hirashima, T1
Otake, S1
Akazawa, N1
Yazawa, T1
Abe, T1
Okada, T1
Kakita, T1
Oikawa, M1
Tsuchiya, T1
de Albuquerque Ribeiro Gondinho, P1
de Barros Silva, PG1
Lisboa, MRP1
Costa, BA1
da Rocha Filho, DR1
Gifoni, MAC1
Lima, MVA1
Junior, RCPL1
Vale, ML1
Lee, JC1
Woo, SM1
Shin, DW1
Kim, J2
Yang, SY1
Kim, MJ1
Kim, JW2
Lee, WJ1
Cha, HS1
Park, P1
Hwang, JH1
Saito, Y1
Makiyama, A1
Tsuji, Y2
Fujiwara, T1
Harihara, Y1
Kurihara, N1
Ando, M2
Kusakawa, G1
Sakai, T1
Uchida, Y1
Takamoto, M1
Kimoto, S1
Hyodo, I2
Miura, Y1
Yamazaki, K2
Hironaka, S1
Boku, N3
Muro, K3
Takeshita, E1
Ishibashi, K2
Koda, K1
Oda, N1
Yoshimatsu, K1
Oya, M1
Yamaguchi, S1
Nakajima, H1
Momma, T1
Maekawa, H1
Yamada, T1
Tanakaya, K1
Gui, Q1
Li, D1
Zhuge, Y1
Xu, C1
Ji, WB1
Hong, KD1
Kim, JS1
Joung, SY1
Um, JW1
Min, BW1
Kuriyama, A1
Endo, K1
Iveson, TJ1
Kerr, RS1
Saunders, MP1
Cassidy, J2
Hollander, NH1
Tabernero, J1
Haydon, A1
Glimelius, B1
Harkin, A1
Allan, K1
McQueen, J1
Scudder, C1
Boyd, KA1
Briggs, A1
Waterston, A1
Medley, L1
Wilson, C1
Ellis, R1
Essapen, S1
Dhadda, AS1
Harrison, M1
Falk, S1
Raouf, S1
Rees, C1
Olesen, RK1
Propper, D1
Bridgewater, J1
Azzabi, A1
Farrugia, D1
Webb, A1
Cunningham, D1
Hickish, T1
Weaver, A1
Gollins, S1
Wasan, HS1
Paul, J1
El-Fatatry, BM1
Ibrahim, OM1
Hussien, FZ1
Mostafa, TM1
Pitarokoili, K1
Höffken, N1
Lönneker, N1
Fisse, AL1
Trampe, N1
Gold, R1
Reinacher-Schick, A1
Yoon, MS1
Yehia, R1
Saleh, S1
El Abhar, H1
Saad, AS1
Schaalan, M1
Soveri, LM1
Lamminmäki, A1
Hänninen, UA1
Karhunen, M1
Bono, P1
Osterlund, P1
Bano, N1
Ikram, R1
Kadakia, KC1
Worrilow, WM1
Coley, H1
Salem, ME1
Nakae, S1
Mizojiri, G1
Fujikawa, M1
Ishida, J1
Yamamoto, M1
Harada, N1
Haji, S1
Toyoda, M1
Senzaki, H1
Chen, Y1
Sun, Y1
Liang, SB1
Zong, JF1
Li, WF1
Chen, M1
Chen, L1
Mao, YP1
Tang, LL1
Guo, Y1
Lin, AH1
Liu, MZ1
Ma, J1
Argyriou, AA3
Cavaletti, G2
Antonacopoulou, A1
Genazzani, AA1
Briani, C2
Bruna, J2
Terrazzino, S1
Velasco, R2
Alberti, P2
Campagnolo, M2
Lonardi, S1
Cortinovis, D2
Cazzaniga, M2
Santos, C1
Psaromyalou, A1
Angelopoulou, A1
Kalofonos, HP4
Murata, S1
Onozawa, S1
Kim, C1
Tajima, H1
Kimata, R1
Uchida, E1
Kumita, S1
Kono, T3
Hata, T1
Morita, S2
Kojima, H2
Takemoto, H1
Shimada, M2
Loprinzi, CL2
Qin, R2
Dakhil, SR1
Fehrenbacher, L1
Flynn, KA1
Atherton, P2
Seisler, D1
Qamar, R1
Lewis, GC1
Grothey, A2
Nagashima, M1
Ooshiro, M1
Moriyama, A1
Sugishita, Y1
Kadoya, K1
Sato, A1
Kitahara, T1
Takagi, R1
Urita, T1
Yoshida, Y1
Tanaka, H1
Oshiro, T1
Okazumi, S1
Katoh, R1
Beijers, AJ2
Mols, F2
Vreugdenhil, G2
Altaf, R1
Lund Brixen, A1
Kristensen, B1
Nielsen, SE1
Tjan-Heijnen, VC1
Faber, CG1
van de Poll-Franse, LV1
Vandamme, M1
Pauwels, W1
Bleecker, JD1
Izquierdo, C1
Frigeni, B1
Cacciavillani, M1
Bergamo, F1
Emi, Y1
Higashijima, J2
Miyake, Y1
Kon, M1
Takahashi, K1
Saeki, H1
Sakaguchi, Y1
Baba, H1
Shirabe, K1
Kakeji, Y1
Hong, TS1
Ryan, DP1
Suenaga, M1
Mizunuma, N2
Matsusaka, S1
Shinozaki, E1
Ozaka, M1
Ogura, M1
Yamaguchi, T1
Pachman, DR1
Seisler, DK1
Smith, EM1
Beutler, AS1
Ta, LE1
Lafky, JM1
Wagner-Johnston, ND1
Ruddy, KJ1
Dakhil, S1
Staff, NP1
Shahriari-Ahmadi, A1
Fahimi, A1
Payandeh, M1
Sadeghi, M1
Kanai, M1
Kawaguchi, T1
Matsumoto, S1
Watanabe, T1
Matsuda, F1
Tsuruta, A1
Yamashita, K1
Tanioka, H1
Inukai, M1
Yamakawa, T1
Yamatsuji, T1
Yoshimitsu, M1
Toyota, K1
Yamano, T1
Nagasaka, T1
Okajima, M1
Tanishima, H1
Tominaga, T1
Kimura, M1
Maeda, T1
Shirai, Y1
Liu, ZF2
Guo, QS1
Zhang, XQ1
Yang, XG1
Guan, F1
Fu, Z1
Wang, MY2
Gu, Y1
Shu, Y1
Xu, Q1
Okada, N1
Miyazaki, T1
Sano, M1
Frye, DK1
Boehnke Michaud, L1
Michalaki, V1
Gennatas, S1
Gennatas, K1
Zhao, JG2
Qiu, F2
Xiong, JP2
Zhang, L2
Xiang, XJ2
Yu, F2
Yan, J2
Zhan, ZY2
Feng, M2
Milla, P1
Airoldi, M1
Weber, G1
Drescher, A1
Jaehde, U1
Cattel, L1
Truchuelo, M1
Vano-Galvan, S1
Pérez, B1
Muñoz-Zato, E1
Jaén, P1
Dong, NN1
Zhang, Q1
Sakakibara, T1
Matsuyoshi, K1
Yuki, K1
Yokota, M1
Itakura, Y1
Adachi, M1
Saito, H1
Matsunaga, Y1
Motokawa, S1
Nakagaki, S1
Yoshida, T1
Muramatsu, T1
Kimura, H1
Ohashi, Y1
Kudou, Y1
Shino, M1
Baena-Cañada, JM1
Martínez, MJ1
García-Olmedo, O1
Jiménez-Bárcenas, R1
Muriel-Cueto, P1
Storey, DJ1
Sakala, M1
McLean, CM1
Phillips, HA1
Dawson, LK1
Wall, LR1
Fallon, MT1
Clive, S1
Stein, A1
Wang, J1
Fan, Y1
Xu, B2
Sparano, JA2
Vrdoljak, E1
Rixe, O1
Manikhas, A1
Medina, C1
Da Costa, SC1
Ro, J1
Rubio, G1
Rondinon, M1
Perez Manga, G1
Peck, R1
Poulart, V1
Conte, P1
Kato, K1
Inaba, Y1
Esaki, T1
Yoshioka, A1
Mizuno, T1
Kusaba, H1
Fujii, H1
Shimada, Y2
Shirao, K2
Schønnemann, KR1
Yilmaz, M1
Andersen, M1
Pfeiffer, P2
Egerton, N1
Inada, M1
Sato, M1
Kitagawa, K1
Kawada, K1
Mitsuma, A1
Sawaki, M1
Fujita, K1
Ando, Y1
Arkenau, HK1
Nishioka, M1
Kurita, N1
Iwata, T1
Morimoto, S1
Yoshikawa, K1
Miyatani, T1
Shibata, M1
Shimura, T1
Nishina, Y1
Gonda, K1
Matsuo, S1
Abe, H1
Yajima, Y1
Nakamura, I1
Ohki, S1
Takenoshita, S1
Yi, SK1
Mak, W1
Yang, CC1
Liu, T1
Cui, J1
Chen, AM1
Purdy, JA1
Monjazeb, AM1
Do, L1
Vahdat, LT1
Thomas, ES1
Roché, HH1
Hortobagyi, GN1
Yelle, L1
Fornier, MN1
Martín, M1
Bunnell, CA1
Mukhopadhyay, P1
Peck, RA1
Perez, EA1
Alejandro, LM1
Behrendt, CE1
Chen, K1
Openshaw, H1
Shibata, S1
Hong, YS1
Lee, SS1
Kim, KP1
Lee, JL1
Kang, YK1
Shin, SJ1
Ahn, JB1
Jung, KH1
Im, SA1
Kim, TY2
Kim, JH1
Park, YS1
Kim, TW1
Vincenzi, B1
Frezza, AM1
Schiavon, G1
Spoto, C1
Silvestris, N1
Addeo, R1
Catalano, V1
Graziano, F1
Santini, D1
Tonini, G1
Tatsushima, Y1
Egashira, N1
Narishige, Y1
Fukui, S1
Kawashiri, T1
Yamauchi, Y1
Oishi, R1
Zhu, Y1
Yang, J1
Jiao, S1
Ji, T1
Twelves, C3
Lin, E1
Morris, JS1
Ayers, GD2
Videtic, GM1
Campbell, C1
Vincent, MD1
Goetz, MP1
Erlichman, C1
Windebank, AJ1
Reid, JM1
Sloan, JA1
Adjei, AA1
Rubin, J1
Pitot, H1
Galanis, E1
Ames, MM1
Goldberg, RM1
Scheithauer, W2
McKendrick, J1
Begbie, S1
Borner, M1
Burns, WI1
Burris, HA1
Jodrell, D1
Koralewski, P1
Levine, EL1
Marschner, N1
Maroun, J1
Garcia-Alfonso, P1
Tujakowski, J1
Van Hazel, G2
Wong, A1
Zaluski, J1
Hahn, P1
Jensen, HA1
Hildebrandt, B1
Dräger, J1
Kerner, T1
Deja, M1
Löffel, J1
Stroszczynski, C1
Ahlers, O1
Felix, R1
Riess, H1
Wust, P1
Kakolyris, S1
Souglakos, J1
Kouroussis, C1
Androulakis, N1
Samonis, G1
Vardakis, N1
Amarantidis, K1
Agelaki, S1
Mavroudis, D1
Xenidis, N1
Georgoulias, V1
Maindrault-Goebel, F1
Tournigand, C1
André, T1
Carola, E1
Mabro, M1
Artru, P1
Louvet, C1
de Gramont, A1
Lee, JJ1
Kim, TM1
Yu, SJ1
Kim, DW1
Joh, YH1
Oh, DY1
Kwon, JH1
Heo, DS1
Bang, YJ1
Kim, NK1
Saif, MW3
Wood, TE1
McGee, PJ1
Diasio, RB2
Lebowitz, PF1
Eng-Wong, J1
Swain, SM1
Berman, A1
Merino, MJ1
Chow, CK1
Venzon, D1
Zia, F1
Danforth, D1
Liu, E1
Zujewski, J1
Mattioli, R1
Massacesi, C1
Recchia, F1
Marcucci, F1
Cappelletti, C1
Imperatori, L1
Pilone, A1
Rocchi, M1
Cesta, A1
Laici, G1
Bonsignori, M1
Lippe, P1
Kopp, HG1
Moerike, K1
Kanz, L1
Hartmann, JT1
Lim, JF1
Tjandra, JJ1
Hiscock, R1
Chao, MW1
Gibbs, P1
Stathopoulos, GP2
Rigatos, SK1
Stathopoulos, JG1
Xynotroulas, JP1
Dimou, E1
Yamada, Y1
Miyata, Y1
Doi, T1
Muto, M1
Hamaguchi, T1
Mera, K1
Yano, T1
Tanigawara, Y1
Hildebrand, J1
Lin, EH1
Curley, SA1
Crane, CC1
Feig, B1
Skibber, J1
Delcos, M1
Vadhan, SR1
Morris, J1
Ross, A1
Brown, T1
Rodriguez-Bigas, MA1
Janjan, N1
Hashmi, S1
Mattison, L1
Donovan, WB1
Muto, O1
Ando, H1
Ono, T1
Itagaki, H1
Kobayashi, Y1
Onuki, M1
Akashi, T1
Tanaka, Y1
Hanaoka, T1
Land, SR1
Kopec, JA1
Cecchini, RS1
Ganz, PA1
Wieand, HS1
Colangelo, LH1
Murphy, K1
Kuebler, JP1
Seay, TE1
Needles, BM1
Bearden, JD1
Colman, LK1
Lanier, KS1
Pajon, ER1
Cella, D1
Smith, RE1
O'Connell, MJ2
Costantino, JP1
Wolmark, N1
Polychronopoulos, P1
Iconomou, G1
Koutras, A1
Makatsoris, T1
Gerolymos, MK1
Gourzis, P1
Assimakopoulos, K1
Chroni, E1
Fountzilas, G1
Dafni, U1
Gogas, H1
Linardou, H1
Briasoulis, E1
Pectasides, D1
Samantas, E1
Bafaloukos, D1
Karina, M1
Papadimitriou, C1
Skarlos, D1
Pisanidis, N1
Papakostas, P1
Markopoulos, C1
Tzorakoeleftherakis, E1
Dimitrakakis, K1
Makrantonakis, P1
Xiros, N1
Polichronis, A1
Varthalitis, I1
Karanikiotis, C1
Dimopoulos, AM1
Schmid, P1
Kühnhardt, D1
Kiewe, P1
Lehenbauer-Dehm, S1
Schippinger, W1
Greil, R1
Lange, W1
Preiss, J1
Niederle, N1
Brossart, P1
Freier, W1
Kümmel, S1
Van de Velde, H1
Regierer, A1
Possinger, K1
Werbrouck, BF1
Pauwels, WJ1
De Bleecker, JL1
Gruenberger, B1
Tamandl, D1
Schueller, J1
Zielinski, C1
Herbst, F1
Gruenberger, T1
Shindo, Y1
Tenma, K1
Imano, H1
Hibino, M1
Yoshino, K1
Herrmann, R1
Spehn, J1
Beyer, JH1
von Franqué, U1
Schmieder, A1
Holzmann, K1
Abel, U1
Buswell, L1
Recht, A1
Clark, J1
Ravikumar, T1
Busse, PM1
Coleman, CN1
Frasci, G1
Leone, F1
Monaco, M1
Cremone, L1
Sapio, U1
Faiella, F1
Espinosa, A1
Persico, G1
Gunderson, LL1
Nelson, H1
Martenson, JA1
Cha, S1
Haddock, M1
Devine, R1
Fieck, JM1
Wolff, B1
Dozois, R1
Lévi, F1
Zidani, R1
Misset, JL1
Soulié, P1
Raymond, E1
Brienza, S1
Cvitkovic, E1
Meropol, NJ1
Rustum, YM1
Creaven, PJ1
Blumenson, LE1
Frank, C1
Rosati, G1
Rossi, A1
Tucci, A1
Pizza, C1
Manzione, L1
Wilson, RH2
Harold, N1
Keith, B1
Dougherty, DS1
Grem, JL2
Oshaughnessy, JA1
Blum, J1
Moiseyenko, V2
Jones, SE1
Miles, D2
Bell, D1
Rosso, R1
Mauriac, L2
Osterwalder, B2
Burger, HU1
Laws, S1
Eckel, F1
Schmelz, R1
Adelsberger, H1
Erdmann, J1
Quasthoff, S1
Lersch, C1
Chang, DZ1
Olencki, T1
Budd, GT1
Peereboom, D1
Ganapathi, R1
Bukowski, R1
Lehky, T1
Thomas, RR1
Quinn, MG1
Floeter, MK1
O'Shaughnessy, J1
Vukelja, S1
Ayoub, JP1
Cervantes, G1
Fumoleau, P1
Jones, S1
Lui, WY1
Verma, S1
Leonard, R1
Carmo-Pereira, J1
Teles, AG1
Costa, FO1
Pimentel, P1
McCarthy, GM1
Skillings, JR1
Sebille, A1
St-Guily, JL1
Angelard, B1
de Stabenrath, A1
Fosså, SD1
Dahl, O1
Hoel, R1
Heier, M1
Loeb, M1
Legha, SS1
Dimery, IW1
Patt, YZ1
Peters, RE1
Chuang, VP1
Wallace, S1
Claghorn, L1
Mavligit, G1

Clinical Trials (28)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase 3, Randomized Study of Adjuvant Immunotherapy With Nivolumab Combined With Ipilimumab Versus Nivolumab Monotherapy After Complete Resection of Stage IIIb/c/d or Stage IV Melanoma[NCT03068455]Phase 31,844 participants (Actual)Interventional2017-04-11Completed
A Phase 2 Randomized Study Comparing the Efficacy and Safety of mFOLFOX6+Panitumumab Combination Therapy and 5-FU/LV+Panitumumab Combination Therapy in the Patients With Chemotherapy-Naive Unresectable Advanced Recurrent Colorectal Carcinoma of KRAS Wild-[NCT02337946]Phase 2164 participants (Actual)Interventional2014-10-16Completed
Temozolomide and Irinotecan Consolidation in Patients With MGMT Silenced, Microsatellite Stable Colorectal Cancer With Persistence of Minimal Residual Disease in Liquid Biopsy After Standard Adjuvant Chemotherapy: the ERASE-TMZ Study[NCT05031975]Phase 235 participants (Anticipated)Interventional2022-05-02Recruiting
The Effect of Monosialotetrahexosylganglioside (GM1) in Prevention of Oxaliplatin Induced Neurotoxicity in Colorectal Cancer Patients Who Received Oxaliplatin-based Adjuvant Chemotherapy: A Multi-center, Randomized, Placebo-controlled Trial[NCT02251977]Phase 3196 participants (Actual)Interventional2014-09-30Completed
Phase II Study of FOLFIRINOX Chemotherapy for Treatment of Advanced Gastric, Gastro-esophageal Junction, and Esophageal Tumors[NCT01928290]Phase 267 participants (Actual)Interventional2013-11-08Completed
Survival Rate and Treatment Cost in Patients With Pancreatic Cancer With the Advent of New Chemotherapeutic Agents in Korea: An Analysis Using NHIS Database and K-PaC Registry Focusing on the Newest One, Liposomal Irinotecan[NCT04984174]54,000 participants (Anticipated)Observational2021-08-04Recruiting
Phase 2 Clinical Study of ART-123 for the Prevention of Cancer Treatment Related Symptoms in Patients With Postoperative Stage II / III Colon Cancer: a Multicenter Randomized Placebo-controlled Double-blind Study to Investigate the Efficacy and Safety of [NCT02792842]Phase 279 participants (Actual)Interventional2016-07-31Completed
Drug Repurposing Using Metformin for Improving the Therapeutic Outcome in Multiple Sclerosis Patients[NCT05298670]Phase 280 participants (Anticipated)Interventional2022-02-01Recruiting
Electro-acupuncture for the Prevention and Treatment of Oxaliplatin-induced Neurotoxicity in Colorectal Cancer Patients: a Prospective, Randomized, Sham-controlled, Double-blinded and Multicenter Study[NCT05798884]150 participants (Anticipated)Interventional2023-05-31Not yet recruiting
The Possible Protective Effect of Pentoxifylline Against Chemotherapy Induced Toxicities in Patients With Colorectal Cancer[NCT05590117]Early Phase 148 participants (Anticipated)Interventional2022-10-11Enrolling by invitation
A Phase III Randomized, Placebo-Controlled, Double-Blind Study of Intravenous Calcium/Magnesium in Two Different Versions to Prevent Oxaliplatin-Induced Sensory Neurotoxicity[NCT01099449]Phase 3362 participants (Actual)Interventional2010-06-30Completed
Comparison of High Tone Therapy and TENS Therapy in Chemotherapy-induced Polyneuropathy[NCT03978585]51 participants (Actual)Interventional2019-09-03Completed
A Phase III Randomized, Placebo-Controlled, Double-Blind Study of Intravenous Calcium/Magnesium to Prevent Oxaliplatin-Induced Sensory Neurotoxicity[NCT00316914]Phase 3104 participants (Actual)Interventional2006-01-31Completed
Effect of Topical Diclofenac on Clinical Outcome in Breast Cancer Patients Treated With Capecitabine: A Randomized Controlled Trial.[NCT05641246]Phase 266 participants (Anticipated)Interventional2022-12-08Active, not recruiting
A Phase I Study of Oxaliplatin, CPT-11, 5-FU and Leucovorin in Patients With Solid Tumors[NCT00005068]Phase 10 participants Interventional2000-01-31Completed
XELOX III. Capecitabine (Xeloda) in Combination With Oxaliplatin (Eloxatin) as First-line Treatment of Patients With Advanced or Metastatic Colorectal Cancer. A Randomized Phase II Study[NCT00212615]Phase 2/Phase 3116 participants (Actual)Interventional2004-02-29Completed
A Pilot Trial of Sequential Primary (Neoadjuvant) Combination Chemotherapy With Docetaxel/Capecitabine (TX) and Doxorubicin/Cyclophosphamide (AC) in Primary Breast Cancer With Evaluation of Chemotherapy Effects on Gene Expression[NCT00005908]Phase 230 participants (Actual)Interventional2000-06-30Completed
Effects of Different Treatment for Anorectal Function of Patients With Rectal Cancer: a Study Protocol for a Prospective, Observational, Controlled, Multicentre Study[NCT05671809]402 participants (Anticipated)Observational [Patient Registry]2023-01-01Not yet recruiting
Randomized Phase 2 Study Comparing Pathological Responses on Colorectal Cancer Metastases After Preoperative Treatment Combining Bevacizumab With FOLFOX or FOLFIRI[NCT01858649]Phase 260 participants (Actual)Interventional2013-05-31Completed
Randomised Phase 2 Study Comparing Pathological Responses Observed on Colorectal Cancer Metastases Resected After Preoperative Treatment Combining Cetuximab With FOLFOX or FOLFIRI in RAS and B-RAF WT Tumors[NCT01858662]Phase 24 participants (Actual)Interventional2014-01-31Terminated (stopped due to due to poor recrutment)
Exploration of New Biologic Factors' Predictive Value , Especially Circulating VE-cadherin in Metastatic Colorectal Adenocarcinoma Patients Treated With Bevacizumab[NCT01405430]63 participants (Actual)Interventional2010-05-31Completed
First Line Infusional 5-Fluorouracil, Folinic Acid and Oxaliplatin for Metastatic Colorectal Cancer or Loco-Regional Recurrency - Role of Chronomodulated Delivery Upon Survival - A Multicenter Randomized Phase III Trial[NCT00003287]Phase 3554 participants (Anticipated)Interventional1998-03-31Completed
Randomized Open-label Trial of Dose Dense, Fixed Dose Capecitabine Compared to Standard Dose Capecitabine in Metastatic Breast Cancer and Advanced/Metastatic Gastrointestinal Cancers.[NCT02595320]Phase 2200 participants (Actual)Interventional2015-10-05Active, not recruiting
Pilot Study of Oxaliplatin in Combination With Capecitabine in Adult Cancer Patients[NCT00019773]Phase 10 participants Interventional1999-07-31Completed
An Open-label Randomized Clinical Trial to Compare the Toxicities and Efficacy of Pharmacokinetically-guided and BSA Fixed Dosing Strategy of Docetaxel and Paclitaxel in Chinese Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma, and Breast Cancer Patie[NCT01891123]300 participants (Anticipated)Interventional2013-06-30Recruiting
Dose Escalation of Xeloda or 5FU Continuous Infusion in Combination With Taxotere and Concurrent Once Weekly, Hypofractionated Chest Radiotherapy for Advanced Non Small Cell Lung Cancer: A Phase I/II Study[NCT00256841]Phase 1/Phase 20 participants (Actual)Interventional2005-09-30Withdrawn (stopped due to Lack of funding)
A Randomized Phase III Study to Investigate the Efficacy and Safety of Docetaxel + Capecitabine vs. Vinorelbine + Capecitabine Followed by Capecitabine Alone as 1st Therapy on Locally Advanced and Metastatic Breast Cancer Patients.[NCT01126138]Phase 3200 participants (Anticipated)Interventional2010-07-31Recruiting
A Prospective, Randomized, Open, Multi-center Phase III Clinical Study Comparing Efficacy and Safety of Sequential T-FEC and TX-XEC as Post-operative Adjuvant Chemotherapy Options for the Treatment of Triple-negative Breast Cancer[NCT01642771]Phase 3636 participants (Anticipated)Interventional2012-06-30Active, not recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Overall Survival (OS) - All Randomized Participants

OS is defined as the time between the date of randomization and the date of death. Median based on Kaplan-Meier Estimates. (NCT03068455)
Timeframe: From randomization to date of death (up to approximately 45 months)

InterventionMonths (Median)
Arm A: Nivo + IpiNA
Arm B: NivoNA

Overall Survival (OS) - All Randomized Participants With PD-L1 Expression Level < 1%

OS is defined as the time between the date of randomization and the date of death. Median based on Kaplan-Meier Estimates. (NCT03068455)
Timeframe: From randomization to date of death (up to approximately 45 months)

InterventionMonths (Median)
Arm A: Nivo + IpiNA
Arm B: NivoNA

Progression-free Survival (PFS) on Next-line Therapy - All Randomized Participants

PFS2 was defined as the time from randomization to the progression date on next-line systemic therapy or the end date of next-line systemic therapy (if progression date not available) or death from any cause (if both progression date and end date not available), and to last known alive date in case of no event (ie, censoring), meaning either (1) no subsequent systemic therapy and no death OR (2) subsequent systemic therapy but no progression date nor end date available and no death. (NCT03068455)
Timeframe: From randomization to progression event (up to approximately 45 months)

InterventionMonths (Median)
Arm A: Nivo + IpiNA
Arm B: NivoNA

Progression-free Survival (PFS) on Next-line Therapy - All Randomized Participants With PD-L1 Expression Level < 1%

PFS2 was defined as the time from randomization to the progression date on next-line systemic therapy or the end date of next-line systemic therapy (if progression date not available) or death from any cause (if both progression date and end date not available), and to last known alive date in case of no event (ie, censoring), meaning either (1) no subsequent systemic therapy and no death OR (2) subsequent systemic therapy but no progression date nor end date available and no death. (NCT03068455)
Timeframe: From randomization to progression event (up to approximately 45 months)

InterventionMonths (Median)
Arm A: Nivo + IpiNA
Arm B: NivoNA

Recurrence-free Survival (RFS) - All Randomized Participants

"RFS was defined as the time between the date of randomization and the date of first recurrence (local, regional or distant metastasis), new primary melanoma (including melanoma in situ), or death (from any cause), whichever occurred first.~Median values based on Kaplan-Meier Estimates." (NCT03068455)
Timeframe: From randomization to Primary Completion Date (up to approximately 3 years)

InterventionMonths (Median)
Arm A: Nivo + IpiNA
Arm B: NivoNA

Recurrence-free Survival (RFS) - All Randomized Participants With PD-L1 Expression Level < 1%

"RFS was defined as the time between the date of randomization and the date of first recurrence (local, regional or distant metastasis), new primary melanoma (including melanoma in situ), or death (from any cause), whichever occurred first.~Median based on Kaplan-Meier Estimates." (NCT03068455)
Timeframe: From randomization to Primary Completion Date (up to approximately 3 years)

InterventionMonths (Median)
Arm A: Nivo + Ipi33.15
Arm B: Nivo27.63

Time From Next Therapy to Second Next Therapy - All Randomized Participants

Time from next treatment to second next treatment was defined as the time from the start date of next systemic therapy to start date of second next systemic therapy. No censoring rules were applied here as analysis was only performed for the subset of participants who received second next treatment. (NCT03068455)
Timeframe: From start of first next systemic therapy to start of second next systemic therapy (up to approximately 28 months)

InterventionMonths (Median)
Arm A: Nivo + Ipi4.60
Arm B: Nivo4.80

Time From Next Therapy to Second Next Therapy - All Randomized Participants With PD-L1 Expression Level < 1%

Time from next treatment to second next treatment was defined as the time from the start date of next systemic therapy to start date of second next systemic therapy. No censoring rules were applied here as analysis was only performed for the subset of participants who received second next treatment. (NCT03068455)
Timeframe: From start of first next systemic therapy to start of second next systemic therapy (up to approximately 28 months)

InterventionMonths (Median)
Arm A: Nivo + Ipi4.44
Arm B: Nivo5.04

Recurrence-free Survival (RFS) by Baseline Tumor PD-L1 Expression

"RFS was defined as the time between the date of randomization and the date of first recurrence (local, regional or distant metastasis), new primary melanoma (including melanoma in situ), or death (from any cause), whichever occurred first.~Median based on Kaplan-Meier Estimates." (NCT03068455)
Timeframe: From randomization to Study Completion Date (up to approximately 45 months)

,
InterventionMonths (Median)
< 1% Tumor PD-L1 Expression≥ 1% Tumor PD-L1 Expression≥ 5% Tumor PD-L1 Expression< 5% Tumor PD-L1 ExpressionNon-quantifiable Tumor PD-L1 Expression
Arm A: Nivo + Ipi33.18NANANANA
Arm B: Nivo25.33NANANANA

Time to Next-Line Therapies - All Randomized Participants

"Time to next therapy was defined as the time from the date of randomization to the start date of next systemic therapy. Participants who did not receive next treatment were censored at the last known alive date.~Time to second next therapy was defined as the time from the date of randomization to the start date of second next systemic therapy. Participants who did not receive second next treatment were censored at the last known alive date." (NCT03068455)
Timeframe: From randomization to start of next therapy or second next therapy (up to approximately 45 months)

,
InterventionMonths (Median)
Time to next therapyTime to second next therapy
Arm A: Nivo + IpiNANA
Arm B: NivoNANA

Time to Next-Line Therapies - All Randomized Participants With PD-L1 Expression Level < 1%

"Time to next therapy was defined as the time from the date of randomization to the start date of next systemic therapy. Participants who did not receive next treatment were censored at the last known alive date.~Time to second next therapy was defined as the time from the date of randomization to the start date of second next systemic therapy. Participants who did not receive second next treatment were censored at the last known alive date" (NCT03068455)
Timeframe: From randomization to start of next therapy or second next therapy (up to approximately 45 months)

,
InterventionMonths (Median)
Time to next therapyTime to second next therapy
Arm A: Nivo + IpiNANA
Arm B: NivoNANA

Overall Survival (OS)

OS was defined as the time from the day of randomization (Day 0) until death by all causes. (NCT02337946)
Timeframe: Up to approximately 31 months

Interventionmonths (Median)
Group ANA
Group BNA

Percentage of Participants With Adverse Events

Safety population was defined as all participants who received at least one dose of protocol treatment after randomization. (NCT02337946)
Timeframe: Up to 28 days after discontinuation of study drug or start of subsequent therapy (data cut off: 31 August 2017; Overall study completion date)

Interventionpercentage of participants (Number)
Group A100
Group B100

Percentage of Participants With Grade 2 or Higher Peripheral Neuropathy

"Peripheral neuropathy was defined as events classified with a preferred term (PT) of peripheral neuropathy according to Standardized MedDRA Queries." (NCT02337946)
Timeframe: Up to 28 days after discontinuation of study drug or start of subsequent therapy (data cut off: 31 August 2017; Overall study completion date)

Interventionpercentage of participants (Number)
Group A30.4
Group B3.7

Progression-Free Survival (PFS)

The PFS is the period from the date of randomization (Day 0) until the date of judgment of progression from the date of randomization, or until death by all causes, whichever comes first. The presence/absence of progressive disease (PD) was determined based on imaging, consideration of clinical PD, or survival research results. PD based on response evaluation criteria in solid tumors (RECIST) is at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (NCT02337946)
Timeframe: Up to approximately 31 months

Interventionmonths (Median)
Group A9.1
Group B9.3

Progression-Free Survival Rate (PFS Rate) at 9 Months After Randomization

PFS rate was defined as the gross percentage of participants who survived with no evidence of progression from the day of randomization (Day 0) until 9 months after Day 0. The presence/absence of progressive disease (PD) was determined based on imaging, consideration of clinical PD, or survival research results. PD based on response evaluation criteria in solid tumors (RECIST) is at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (NCT02337946)
Timeframe: Up to 9 months after randomization

Interventionpercentage of participants (Number)
Group A46.4
Group B47.4

Response Rate (RR)

RR was defined as the percentage of participants who had shown complete response (CR) or partial response (PR) as the best overall response in accordance with the RECIST 1.1 criteria after randomization. The best overall response was CR, followed by PR, stable disease (SD), progressive disease (PD), and not evaluable (NE). CR: disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to <10 mm. PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters as the best overall response after randomization., SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). (NCT02337946)
Timeframe: Up to approximately 31 months

Interventionpercentage of participants (Number)
Group A80.4
Group B87.7

Time to Treatment Failure (TTF)

TTF was defined as the time from the day of randomization (Day 0) until the day of protocol treatment discontinuation determination, the day of PD decision during protocol treatment, or death from any cause, whichever came the earliest. (NCT02337946)
Timeframe: Up to approximately 31 months

Interventionmonths (Median)
Group A8.1
Group B6.1

Percentage of Participants With Adverse Events by Severity Graded Using the Common Terminology Criteria for Adverse Events (CTCAE) Grade

An AE is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medical treatment or procedure that may or may not be considered related to the medical treatment or procedure. Grade refers to the severity of the AE. The CTCAE displays Grades 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: Grade 1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2 Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living (ADL). Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care ADL. Grade 4 Life-threatening consequences; urgent intervention indicated. Grade 5 Death related to AE. (NCT02337946)
Timeframe: Up to 28 days after discontinuation of study drug or start of subsequent therapy (data cut off: 31 August 2017; Overall study completion date)

,
Interventionpercentage of participants (Number)
Grade 1Grade 2Grade 3, 4 and 5
Group A019.680.4
Group B027.872.2

Percentage of Participants With Grade 3 or Higher Skin Toxicity

"Skin toxicity was defined as events classified with an system organ class of Skin and subcutaneous tissue disorders or a preferred term of paronychia." (NCT02337946)
Timeframe: Up to 28 days after discontinuation of study drug or start of subsequent therapy (data cut off: 31 August 2017; Overall study completion date)

,
Interventionpercentage of participants (Number)
Skin and subcutaneous tissue disordersParonychia
Group A17.97.1
Group B18.59.3

Clinical Benefit Rate

"Clinical benefit rate is the percentage of combined patients who have achieved complete response (CR), partial response (PR), and stable disease (SD)~CR: Disappearance of all target lesions, non-target lesions, and normalization of tumor marker level. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm~PR: At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters~SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study." (NCT01928290)
Timeframe: Through completion of treatment (estimated to be 4 months)

InterventionParticipants (Count of Participants)
Arm A: FOLFIRINOX (HER2-negative)33
Arm B: FOLFIRINOX & Trastuzumab (HER2-positive)22

Duration of Response

Time measurement criteria are met for CR or PR (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented (NCT01928290)
Timeframe: Through 1 year after completion of treatment (median follow-up 16.2 months - 95% CI 4.7-42.5 months)

Interventionmonths (Median)
Arm A: FOLFIRINOX (HER2-negative)5.8
Arm B: FOLFIRINOX & Trastuzumab (HER2-positive)10.5

Number of Participants With an Objective Response

"Objective response (defined as complete response (CR) + partial response (PR) by RECIST 1.1 criteria)~CR: Disappearance of all target lesions, non-target lesions, and normalization of tumor marker level. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm.~PR: At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters." (NCT01928290)
Timeframe: Through completion of treatment (estimated to be 4 months)

InterventionParticipants (Count of Participants)
Arm A: FOLFIRINOX (HER2-negative)25
Arm B: FOLFIRINOX & Trastuzumab (HER2-positive)22

Overall Survival (OS)

Overall survival is defined as the time interval from date of diagnosis to date of death from any cause. (NCT01928290)
Timeframe: Through 1 year after completion of treatment (median follow-up 16.2 months - 95% CI 4.7-42.5 months)

Interventionmonths (Median)
Arm A: FOLFIRINOX (HER2-negative)15.5
Arm B: FOLFIRINOX & Trastuzumab (HER2-positive)19.6

Progression Free Survival

Duration of time from start of treatment to time of progression or death, whichever occurs first. (NCT01928290)
Timeframe: Through 1 year after completion of treatment (median follow-up 16.2 months - 95% CI 4.7-42.5 months)

Interventionmonths (Median)
Arm A: FOLFIRINOX (HER2-negative)8.4
Arm B: FOLFIRINOX & Trastuzumab (HER2-positive)13.8

Time to Progression (TTP)

Duration of time from start of treatment to time of progression. Progression is defined as At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (NCT01928290)
Timeframe: Through 1 year after completion of treatment (median follow-up 16.2 months - 95% CI 4.7-42.5 months)

Interventionmonths (Median)
Arm A: FOLFIRINOX (HER2-negative)8.0
Arm B: FOLFIRINOX & Trastuzumab (HER2-positive)13.9

Toxicity and Tolerability (Arm A and Arm B) as Measured by the Number of Participants With Grade 3 or Higher Adverse Events

(NCT01928290)
Timeframe: 30 days after completion of treatment (estimated to be 5 months)

,
Interventionparticipants (Number)
AnemiaFebrile neutropeniaAnal FistulaDiarrheaHematemesisNauseaPeripheral ischemiaVomitingFatigueLaparoscopy surgeryPainSepsisLung infectionPneumoniaHypernatremiaNeutrophil count decreasedPlatelet count decreasedAnorexiaDehydrationHypokalemiaBack painPeripheral sensory neuropathySyncopeDyspneaPleural embolismSkin infectionThromboembolic eventAbdominal painEnterocolitisHemorrhoidsG-tube infectionNeutropenic entercolitisAlkaline phosphatase increased
Arm A: FOLFIRINOX (HER2-negative)1214121341111111933411211114000000
Arm B: FOLFIRINOX & Trastuzumab (HER2-positive)000502010000000800020010000111111

Area Under the Curve (AUC) of European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire of Chemotherapy-induced Peripheral Neuropathy (EORTC QLQ-CIPN20) Motor Neuropathy Subscale Scores

The oxaliplatin-induced motor neuropathy as repeatedly measured by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire of Chemotherapy-induced peripheral neuropathy (EORTC QLQ-CIPN20) motor neuropathy subscale during the chemotherapy. This is a multivariate repeated measurement of CIPN with possibly variable cycles for every patient. The CIPN motor neuropathy subscale will be calculated by standard scoring algorithm and converted to 0-100 scale, where higher scores represent a higher quality of life. Rather than choosing the CIPN20 motor neuropathy subscale at a fixed cycle of chemotherapy, we will adopt a summary measure, area under the curve (AUC) of CIPN20 motor neuropathy subscale as the endpoint. This AUC will be prorated by the number of chemotherapy cycles patients received. (NCT01099449)
Timeframe: Up to 18 Months

InterventionAUC QLQ-CIPN20 Motor Neuropathy Score (Mean)
Calcium Gluconate + Magnesium Sulfate (Pre and Post)94.1
Placebo (Pre and Post)93.3
Calcium Gluconate + Magnesium Sulfate (Pre), Placebo (Post)91.6

Area Under the Curve (AUC) of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire of Chemotherapy-induced Peripheral Neuropathy (EORTC QLQ-CIPN20) Autonomic Neuropathy Subscale Scores

The oxaliplatin-induced autonomic neuropathy as repeatedly measured by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire of Chemotherapy-induced peripheral neuropathy (EORTC QLQ-CIPN20) autonomic subscale during the chemotherapy. This is a multivariate repeated measurement of CIPN with possibly variable cycles for every patient. The CIPN autonomic subscale will be calculated by standard scoring algorithm and converted to 0-100 scale, where higher scores represent a higher quality of life. Rather than choosing the CIPN20 autonomic subscale at a fixed cycle of chemotherapy, we will adopt a summary measure, area under the curve (AUC) of CIPN20 autonomic subscale as the endpoint. This AUC will be prorated by the number of chemotherapy cycles patients received. (NCT01099449)
Timeframe: Up to 18 months

Interventionscore on a scale (Mean)
Calcium Gluconate + Magnesium Sulfate (Pre and Post)89.8
Placebo (Pre and Post)86.7
Calcium Gluconate + Magnesium Sulfate (Pre), Placebo (Post)84.5

Cumulative Oxaliplatin Doses That Can be Administered Without Dose-limiting Chronic Neurotoxicity

A patient has a dose-limiting chronic neurotoxicity when they discontinue oxaliplatin-based chemotherapy because of neurotoxicity. (NCT01099449)
Timeframe: Up to 18 months

InterventionDoses (Mean)
Calcium Gluconate + Magnesium Sulfate (Pre and Post)8.1
Placebo (Pre and Post)8.4
Calcium Gluconate + Magnesium Sulfate (Pre), Placebo (Post)8.0

Incidence of Calcium Gluconate and Magnesium Sulfate-induced Adverse Events as Measured by CTCAE Version 4.0

(NCT01099449)
Timeframe: Up to 18 months

InterventionNumber of reported Adverse Events (Number)
Arm I290
Arm II259
Arm III296

Percentage of Patients Discontinuing Oxaliplatin-based Chemotherapy Because of Neurotoxicity

(NCT01099449)
Timeframe: Up to 18 months

Interventionpercentage of patients (Number)
Calcium Gluconate + Magnesium Sulfate (Pre and Post)34.7
Placebo (Pre and Post)27.7
Calcium Gluconate + Magnesium Sulfate (Pre), Placebo (Post)30.5

Sensory Area Under the Curve(AUC) Score. Oxaliplatin-induced Sensory Neuropathy as Repeatedly Measured by the EORTC QLQ-CIPN20 Sensory Subscale During Chemotherapy

The oxaliplatin-induced sensory neuropathy as repeatedly measured by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire of Chemotherapy-induced peripheral neuropathy (EORTC QLQ-CIPN20) sensory subscale during the chemotherapy. This is a multivariate repeated measurement of CIPN with possibly variable cycles for every patient. The CIPN sensory subscale will be calculated by standard scoring algorithm and converted to 0-100 scale, where higher scores represent a higher quality of life. Rather than choosing the CIPN20 sensory subscale at a fixed cycle of chemotherapy, we will adopt a summary measure, area under the curve (AUC) of CIPN20 sensory subscale as the primary endpoint. This AUC will be prorated by the number of chemotherapy cycles patients received. (NCT01099449)
Timeframe: Up to 18 months

Interventionscore on a scale (Mean)
Calcium Gluconate + Magnesium Sulfate (Pre and Post)89.2
Placebo (Pre and Post)88.3
Calcium Gluconate + Magnesium Sulfate (Pre), Placebo (Post)87.1

Area Under the Curve (AUC) of Patient-reported Quality of Life (QOL) as Measured by the Supplemental QOL Questionnaire

This is a multivariate repeated measurement of CIPN with possibly variable cycles for every patient. The supplemental quality of life (QOL) subscale will be calculated by standard scoring algorithm and converted to 0-100 scale, where higher scores represent a higher quality of life. Rather than choosing the subscale at a fixed cycle of chemotherapy, we will adopt a summary measure, area under the curve (AUC) . This AUC will be prorated by the number of chemotherapy cycles patients received. (NCT01099449)
Timeframe: Up to 18 months

,,
Interventionscore on a scale (Mean)
DiarrheaConstipationStomach CrampingBowel ProblemsSwallowingNumbness in finger and toesTingling in finger and toes
Arm I86.790.192.889.191.283.478.9
Arm II86.288.890.688.587.681.876.5
Arm III84.588.089.484.686.780.076.3

Percentage of Patients Experiencing Grade 2+ and Grade 3+ Chronic Cumulative Neurotoxicity.

Grades are determined by the National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI CTCAE version 4.0) and oxaliplatin-specific neurotoxicity scale, during and after chemotherapy. Higher grades symbolize greater severity of the adverse event. (NCT01099449)
Timeframe: Up to 18 months

,,
Interventionpercentage of patients (Number)
grade 2+grade 3+
Calcium Gluconate + Magnesium Sulfate (Pre and Post)42.77.7
Calcium Gluconate + Magnesium Sulfate (Pre), Placebo (Post)46.17.8
Placebo (Pre and Post)44.87.8

Percentage of Patients With Acute Neuropathy Associated With Oxaliplatin

This is the percent of patients who scored >=50 in all sequences of all cycles by arm for side effect Q1: Sensitivity to touching cold. This is a> repeated measurement of CIPN with possibly variable cycles for every patient. The CIPN subscale will be calculated by standard scoring algorithm and converted to 0-100 scale. Where 0 is no sensitivity and 100 is as bad as it can be. (NCT01099449)
Timeframe: Up to 18 months

,,
Interventionpercentage of patients (Number)
Cycle 1Cycle 2Cycle 3Cycle 4Cycle 5Cycle 6Cycle 7Cycle 8Cycle 9Cycle 10Cycle 11Cycle 12
Arm I102432343431353234292827
Arm II132733373337343437393945
Arm III142832363933343332303332

Time to Onset of Grade 2+ and Grade 3+ Chronic Cumulative Neurotoxicity and the Duration of the Chronic Cumulative Neurotoxicity During and After Chemotherapy

Time to onset of grade 2+ and grade 3+ chronic cumulative neurotoxicity, the duration of the chronic cumulative neurotoxicity during and after the adjuvant oxaliplatin-based chemotherapy. Grades are determined by the National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI CTCAE version 4.0) and oxaliplatin-specific neurotoxicity scale, during and after chemotherapy. Higher grades symbolize greater severity of the adverse event. (NCT01099449)
Timeframe: Up to 18 months

,,
InterventionDays (Median)
Time to Grade 2 NeuropathyTime to Grade 3 Neuropathy
Calcium Gluconate + Magnesium Sulfate (Pre and Post)171NA
Calcium Gluconate + Magnesium Sulfate (Pre), Placebo (Post)171NA
Placebo (Pre and Post)173208

Average Duration of Chronic Neuropathic Toxicity

Neuropathic adverse events were assessed by CTCAE v3.0. (NCT00316914)
Timeframe: 127 days

Interventiondays (Median)
Ca/Mg81
Placebo72

Percentage of Patients Discontinuing Therapy for Chronic Neurotoxicity

Neurotoxicity were assessed by CTCAE v3.0. (NCT00316914)
Timeframe: 127 days

InterventionPercentage of Participants (Number)
Ca/Mg46
Placebo55.8

Percentage of Patients With Acute Neuropathic Adverse Event

Acute neuropathic toxicities were measured using the Symptom Experience Diary and supplemental quality of life questions in the scale of 0 (no symptom) to 10 (worst symptom). The item score was reversed and transformed into 0 (low QOL) to 100 (best QOL) scale for analysis. Any score greater than 0 was considered having acute neuropathy. (NCT00316914)
Timeframe: 127 days

InterventionPercentage of participants (Number)
Ca/Mg88
Placebo90

Percentage of Patients With Oxaliplatin-induced Grade 2+ Chronic Neuropathic Adverse Event

Neuropathic adverse events were assessed by Common Terminology Criteria for Adverse Events (CTCAE) v3.0. Neurotoxicity evaluation grade: loss of deep tendon reflexes or paresthesia, including tingling, but not interfering with function (Grade 1); objective sensory alteration or paresthesia, including tingling, interfering with function, but not with activities of daily living (Grade 2); sensory alteration or paresthesia interfering with activities of daily living (Grade 3); permanent sensory losses that are disabling (Grade 4) (NCT00316914)
Timeframe: 127 days

InterventionPercentage of participants (Number)
Ca/Mg22
Placebo41

Time to Onset of Grade 2+ Chronic Neurotoxicity

Neurotoxicity were assessed by Common Terminology Criteria for Adverse Events (CTCAE) v3.0. (NCT00316914)
Timeframe: 127 days

InterventionDays (Median)
Ca/MgNA
Placebo18.1

Time to Onset of Grade 3+ Chronic Neurotoxicity

Neurotoxicity was assessed by CTCAE v3.0. (NCT00316914)
Timeframe: 127 days

InterventionDays (Median)
Ca/MgNA
PlaceboNA

Change From Baseline in Fatigue Score at One Month

Fatigue was measured by Brief Fatigue Inventory in the scale of 0 (no fatigue) to 10 (fatigue as bad as you can imagine). The item score was reversed and transformed into 0 (low quality of life (QOL)) to 100 (best QOL) scale for analysis. Change: score at one month minus score at baseline. (NCT00316914)
Timeframe: Baseline and One month

,
Interventionunits on a scale (Mean)
Fatigue NOWFatigue USUALFatigue WORST
Ca/Mg1.03.10.0
Placebo-2.8-1.6-1.6

Change From Baseline in Quality of Life (QOL) at One Month

Quality of Life (QOL) were measured using the Symptom Experience Diary and supplemental quality of life questions. Item score range: 0 (no symptom) to 10 (worst symptom). The score was reversed and transformed into 0 (low QOL) to 100 (best QOL) scale for analysis. Change: score at one month minus score at baseline. (NCT00316914)
Timeframe: Baseline and One month

,
InterventionUnits on a scale (Mean)
Fatigue WORSTWalkingButtoning Shirt or Tying LacesDiarrheaConstipationAbdominal CrampingBowel Problems with Normal ActivityShortness of Breath (Week 2 - Baseline)Swallowing (Week 2 - Baseline)Numbness in Fingers, Toes (Week 2 - Baseline)Tingling in Fingers, Toes (Week 2 - Baseline)
Ca/Mg0.0-2.5-2.0-7.1-2.9-2.5-3.2-0.7-7.5-8.3-14.8
Placebo-1.60.20.4-10.40.41.3-9.12.12.1-9.6-20.4

Incidence of Calcium Magnesium (CaMg)-Induced Adverse Event

Adverse Events were measured using CTCAE V3.0. (NCT00316914)
Timeframe: 127 days

,
InterventionPercentage of Participants (Number)
Abdominal InfectionAcne NOSAnemiaAnorexiaClostridial InfectionConstipationDehydrationDiarrhea-No ColostomDry SkinErythema MultiformeFatigueHypercalcemiaHyperglycemiaHypermagnesemiaHypersensitivityHypokalemiaHypomagnesemiaHyponatremiaInfectionIschemia-CerebralIschemia/InfarctionLaryngeal DiscomfortLeukopeniaMuscle WeaknessMyalgiaNauseaNeuro-motorNeuro-sensoryNeutropeniaOral cavity MS CEPain-AbdominalPain-ChestPain-HeadacheRash/DesquamationSkin Rxn-Hand/FootStomatitisTasteThrombocytopeniaThrombosisUrticariaVasc Access ComplicationVomiting
Ca/Mg2244042268041002146404002062460421820004422260234
Placebo024224767320252018022022021000714123308240222242033

Number of Participants With Adverse Events

Here is the number of participants with adverse events. For the detailed list of adverse events see the adverse event module. (NCT00005908)
Timeframe: 6 years

InterventionParticipants (Number)
Dose A-Cohort 1-Arm 1-Docetaxel & Capecitabine9
Dose B-Cohort 2-Arm 2 Reduced Dose-Docetaxel & Capecitabine20

Complementary Deoxyribonucleic Acid (cDNA) Expression

Patients were classified as responders or non-responders based on change in tumor size by clinical exam and pathologic response.For instance, patients with a pathological complete response, micro-invasive disease at surgery, or clinical complete response after four cycles of treatment were considered responders. Changes in gene expression associated with treatment was assessed before/after chemotherapy. All gene expression summary intensities below 50 were thresholded to the value of 50 and genes showing variability significantly smaller than the median gene variability were screened out. (NCT00005908)
Timeframe: 6 years

,
InterventionParticipants (Number)
RespondersNon-responders
Dose A-Cohort 1-Arm 1-Docetaxel & Capecitabine82
Dose B-Cohort 2-Arm 2 Reduced Dose-Docetaxel & Capecitabine713

Number of Participants, e.g. Responders and Non-responders With a Percent Change in Expression Patterns After Chemotherapy With Changes in Expression Patterns After Chemotherapy in Preclinical Models

Patients were classified as responders or non-responders based on change in tumor size by clinical exam and pathologic response.For instance, patients with a pathological complete response, micro-invasive disease at surgery, or clinical complete response after four cycles of treatment were considered responders. Changes in gene expression associated with treatment was assessed before/after chemotherapy. All gene expression summary intensities below 50 were thresholded to the value of 50 and genes showing variability significantly smaller than the median gene variability were screened out. (NCT00005908)
Timeframe: 6 years

InterventionParticipants (Number)
RespondersNon-responders
Dose A & B-Cohort 1 & 2-Arm 1 & 2-Docetaxel & Capecitabine813

Overall Clinical Response Rate

Overall response rate is defined as the percentage of participants with a CR (complete disappearance of all target lesions), PR (a 30% decrease in the sum of the longest diameter of target lesions) determined by clinical measurements per the Response Evaluation Criteria in Solid Tumors (RECIST) and/or a complete pathologic response (disappearance of all invasive tumor pathologically or presence of ductal carcinoma in situ) per the Chevallier criteria. For details about the RECIST or Chevallier criteria see the protocol link module. (NCT00005908)
Timeframe: 6 years

InterventionPercentage of participants (Number)
Complete ResponsePartial ResponseComplete pathologic response
Dose A & B-Cohort 1 & 2-Arm 1& 2-Docetaxel & Capecitabine315910

Reviews

10 reviews available for fluorouracil and Peripheral Nervous System Diseases

ArticleYear
Goshajinkigan for prevention of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2018, Volume: 26, Issue:4

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colorectal

2018
A systematic review on chronic oxaliplatin-induced peripheral neuropathy and the relation with oxaliplatin administration.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2014, Volume: 22, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; Leucovor

2014
Capecitabine-based combination therapy for breast cancer: implications for nurses.
    Oncology nursing forum, 2009, Volume: 36, Issue:1

    Topics: Alopecia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marr

2009
The optimal therapeutic use of ixabepilone in patients with locally advanced or metastatic breast cancer.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2009, Volume: 15, Issue:2

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabin

2009
Interaction between capecitabine and brivudin in a patient with breast cancer.
    Nature reviews. Clinical oncology, 2010, Volume: 7, Issue:1

    Topics: Aged; Anemia, Aplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protoc

2010
Ixabepilone.
    Clinical journal of oncology nursing, 2010, Volume: 14, Issue:1

    Topics: Anthracyclines; Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Capecitabi

2010
Optimizing ixabepilone treatment schedules in patients with advanced or metastatic breast cancer.
    Cancer chemotherapy and pharmacology, 2010, Volume: 66, Issue:6

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com

2010
Can capecitabine replace 5-FU/leucovorin in combination with oxaliplatin for the treatment of advanced colorectal cancer?
    Oncology (Williston Park, N.Y.), 2002, Volume: 16, Issue:12 Suppl N

    Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials

2002
Neurological complications of cancer chemotherapy.
    Current opinion in oncology, 2006, Volume: 18, Issue:4

    Topics: Antineoplastic Agents; Capecitabine; Central Nervous System; Deoxycytidine; Fluorouracil; Humans; Ma

2006
[Oxaliplatin: the first DACH platinum in clinical practice].
    Bulletin du cancer, 1997, Volume: 84, Issue:6

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female;

1997

Trials

59 trials available for fluorouracil and Peripheral Nervous System Diseases

ArticleYear
Final Analysis of 3 Versus 6 Months of Adjuvant Oxaliplatin and Fluoropyrimidine-Based Therapy in Patients With Stage III Colon Cancer: The Randomized Phase III ACHIEVE Trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022, 10-10, Volume: 40, Issue:29

    Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colonic Neopla

2022
SAPPHIRE: a randomised phase II study of planned discontinuation or continuous treatment of oxaliplatin after six cycles of modified FOLFOX6 plus panitumumab in patients with colorectal cancer.
    European journal of cancer (Oxford, England : 1990), 2019, Volume: 119

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms

2019
Efficacy and Long-term Peripheral Sensory Neuropathy of 3 vs 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Colon Cancer: The ACHIEVE Phase 3 Randomized Clinical Trial.
    JAMA oncology, 2019, 11-01, Volume: 5, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol

2019
JOIN trial: treatment outcome and recovery status of peripheral sensory neuropathy during a 3-year follow-up in patients receiving modified FOLFOX6 as adjuvant treatment for stage II/III colon cancer.
    Cancer chemotherapy and pharmacology, 2019, Volume: 84, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva

2019
Phase III randomized, placebo-controlled, double-blind study of monosialotetrahexosylganglioside for the prevention of oxaliplatin-induced peripheral neurotoxicity in stage II/III colorectal cancer.
    Cancer medicine, 2020, Volume: 9, Issue:1

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Disease-F

2020
Evaluation of FOLFOX or CAPOX reintroduction with or without bevacizumab in relapsed colorectal cancer patients treated with oxaliplatin as adjuvant chemotherapy (REACT study).
    International journal of clinical oncology, 2020, Volume: 25, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecit

2020
FOLFIRINOX for the Treatment of Advanced Gastroesophageal Cancers: A Phase 2 Nonrandomized Clinical Trial.
    JAMA oncology, 2020, 08-01, Volume: 6, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Esophageal Ne

2020
Protective effect of the oral administration of cystine and theanine on oxaliplatin-induced peripheral neuropathy: a pilot randomized trial.
    International journal of clinical oncology, 2020, Volume: 25, Issue:10

    Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Cy

2020
A placebo-controlled, double-blind, randomized study of recombinant thrombomodulin (ART-123) to prevent oxaliplatin-induced peripheral neuropathy.
    Cancer chemotherapy and pharmacology, 2020, Volume: 86, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Administration

2020
Efficacy of Exercise Rehabilitation Program in Relieving Oxaliplatin Induced Peripheral Neurotoxicity.
    Asian Pacific journal of cancer prevention : APJCP, 2021, Mar-01, Volume: 22, Issue:3

    Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Digestiv

2021
3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial.
    The Lancet. Oncology, 2018, Volume: 19, Issue:4

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad

2018
Role of metformin in oxaliplatin-induced peripheral neuropathy in patients with stage III colorectal cancer: randomized, controlled study.
    International journal of colorectal disease, 2018, Volume: 33, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Egypt; Fluorouracil; Humans; L

2018
Role of metformin in oxaliplatin-induced peripheral neuropathy in patients with stage III colorectal cancer: randomized, controlled study.
    International journal of colorectal disease, 2018, Volume: 33, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Egypt; Fluorouracil; Humans; L

2018
Role of metformin in oxaliplatin-induced peripheral neuropathy in patients with stage III colorectal cancer: randomized, controlled study.
    International journal of colorectal disease, 2018, Volume: 33, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Egypt; Fluorouracil; Humans; L

2018
Role of metformin in oxaliplatin-induced peripheral neuropathy in patients with stage III colorectal cancer: randomized, controlled study.
    International journal of colorectal disease, 2018, Volume: 33, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Egypt; Fluorouracil; Humans; L

2018
L-Carnosine protects against Oxaliplatin-induced peripheral neuropathy in colorectal cancer patients: A perspective on targeting Nrf-2 and NF-κB pathways.
    Toxicology and applied pharmacology, 2019, 02-15, Volume: 365

    Topics: Adult; Aged; Anti-Inflammatory Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants;

2019
Progress report of a randomized trial comparing long-term survival and late toxicity of concurrent chemoradiotherapy with adjuvant chemotherapy versus radiotherapy alone in patients with stage III to IVB nasopharyngeal carcinoma from endemic regions of Ch
    Cancer, 2013, Jun-15, Volume: 119, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemother

2013
Negative-balance isolated pelvic perfusion in patients with incurable symptomatic rectal cancer: results and drug dose correlation to adverse events.
    Acta radiologica (Stockholm, Sweden : 1987), 2014, Volume: 55, Issue:7

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Ca

2014
Goshajinkigan oxaliplatin neurotoxicity evaluation (GONE): a phase 2, multicenter, randomized, double‑blind, placebo‑controlled trial of goshajinkigan to prevent oxaliplatin‑induced neuropathy.
    Cancer chemotherapy and pharmacology, 2013, Volume: 72, Issue:6

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols

2013
Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance).
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Apr-01, Volume: 32, Issue:10

    Topics: Administration, Intravenous; Aged; Antineoplastic Combined Chemotherapy Protocols; Calcium; Cold Tem

2014
Preventive effect of Goshajinkigan on peripheral neurotoxicity of FOLFOX therapy (GENIUS trial): a placebo-controlled, double-blind, randomized phase III study.
    International journal of clinical oncology, 2015, Volume: 20, Issue:4

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Double-Blind Method; Dru

2015
Phase II study of reintroduction of oxaliplatin for advanced colorectal cancer in patients previously treated with oxaliplatin and irinotecan: RE-OPEN study.
    Drug design, development and therapy, 2015, Volume: 9

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemo

2015
Clinical Course of Oxaliplatin-Induced Neuropathy: Results From the Randomized Phase III Trial N08CB (Alliance).
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, Oct-20, Volume: 33, Issue:30

    Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Calcium Compounds; Chronic Disease; C

2015
Feasibility of sequential adjuvant chemotherapy with a 3-month oxaliplatin-based regimen followed by 3 months of capecitabine in patients with stage III and high-risk stage II colorectal cancer: JSWOG-C2 study.
    Drug design, development and therapy, 2016, Volume: 10

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemot

2016
Biweekly oxaliplatin in combination with continuous infusional 5-fluorouracil and leucovorin (modified FOLFOX-4 regimen) as first-line chemotherapy for elderly patients with advanced gastric cancer.
    American journal of clinical oncology, 2008, Volume: 31, Issue:3

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedul

2008
A study of weekly paclitaxel plus 5-fluorouracil and cisplatin for patients with advanced or recurrent inoperable gastric cancer.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2009, Volume: 63, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; C

2009
Low-dose capecitabine plus docetaxel as first-line therapy for metastatic breast cancer: phase II results.
    Anti-cancer drugs, 2009, Volume: 20, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcino

2009
A phase II study of modified FOLFOX as first-line chemotherapy in elderly patients with advanced gastric cancer.
    Anti-cancer drugs, 2009, Volume: 20, Issue:4

    Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease Progre

2009
Administration of reduced glutathione in FOLFOX4 adjuvant treatment for colorectal cancer: effect on oxaliplatin pharmacokinetics, Pt-DNA adduct formation, and neurotoxicity.
    Anti-cancer drugs, 2009, Volume: 20, Issue:5

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Chemotherapy

2009
[Oxaliplatin combined with capecitabine as first-line chemotherapy for patients with advanced gastric cancer].
    Ai zheng = Aizheng = Chinese journal of cancer, 2009, Volume: 28, Issue:4

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol

2009
Ixabepilone plus capecitabine for Chinese patients with metastatic breast cancer progressing after anthracycline and taxane treatment.
    Cancer chemotherapy and pharmacology, 2010, Volume: 66, Issue:3

    Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Asian People; Breast Ne

2010
Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Jul-10, Volume: 28, Issue:20

    Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capec

2010
A multicenter phase-II study of 5-FU, leucovorin and oxaliplatin (FOLFOX6) in patients with pretreated metastatic colorectal cancer.
    Japanese journal of clinical oncology, 2011, Volume: 41, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Surv

2011
The Kampo medicine, Goshajinkigan, prevents neuropathy in patients treated by FOLFOX regimen.
    International journal of clinical oncology, 2011, Volume: 16, Issue:4

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drugs

2011
A phase II study of capecitabine plus oxaliplatin as first-line chemotherapy in elderly patients with advanced gastric cancer.
    Chemotherapy, 2012, Volume: 58, Issue:1

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine

2012
A phase II study of bevacizumab, oxaliplatin, and capecitabine in patients with previously untreated metastatic colorectal cancer: a prospective, multicenter trial of the Korean Cancer Study Group.
    American journal of clinical oncology, 2014, Volume: 37, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy

2014
Ganglioside-monosialic acid (GM1) prevents oxaliplatin-induced peripheral neurotoxicity in patients with gastrointestinal tumors.
    World journal of surgical oncology, 2013, Jan-25, Volume: 11

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Co

2013
Phase I and pharmacokinetic study of two different schedules of oxaliplatin, irinotecan, Fluorouracil, and leucovorin in patients with solid tumors.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Oct-15, Volume: 21, Issue:20

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Sched

2003
Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2003, Volume: 14, Issue:12

    Topics: Administration, Oral; Adult; Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic;

2003
Whole-body hyperthermia in the scope of von Ardenne's systemic cancer multistep therapy (sCMT) combined with chemotherapy in patients with metastatic colorectal cancer: a phase I/II study.
    International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group, 2004, Volume: 20, Issue:3

    Topics: Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemoth

2004
Dose escalation study on oxaliplatin and capecitabine (Xeloda) in patients with advanced solid tumors.
    Oncology, 2004, Volume: 66, Issue:4

    Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Cap

2004
Oxaliplatin reintroduction in patients previously treated with leucovorin, fluorouracil and oxaliplatin for metastatic colorectal cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2004, Volume: 15, Issue:8

    Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Ne

2004
Single-agent capecitabine in patients with metastatic colorectal cancer refractory to 5-fluorouracil/leucovorin chemotherapy.
    Japanese journal of clinical oncology, 2004, Volume: 34, Issue:7

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic C

2004
A phase II trial of neoadjuvant docetaxel and capecitabine for locally advanced breast cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Oct-15, Volume: 10, Issue:20

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms;

2004
High activity and reduced neurotoxicity of bi-fractionated oxaliplatin plus 5-fluorouracil/leucovorin for elderly patients with advanced colorectal cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2005, Volume: 16, Issue:7

    Topics: Activities of Daily Living; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols;

2005
Efficacy and tolerability of oxaliplatin plus irinotecan 5-fluouracil and leucovorin regimen in advanced stage colorectal cancer patients pretreated with irinotecan 5-fluouracil and leucovorin.
    American journal of clinical oncology, 2005, Volume: 28, Issue:6

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers,

2005
Phase I/II study of oxaliplatin with weekly bolus fluorouracil and high-dose leucovorin (ROX) as first-line therapy for patients with colorectal cancer.
    Japanese journal of clinical oncology, 2006, Volume: 36, Issue:4

    Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Dose-Respo

2006
Retrospective study of capecitabine and celecoxib in metastatic colorectal cancer: potential benefits and COX-2 as the common mediator in pain, toxicities and survival?
    American journal of clinical oncology, 2006, Volume: 29, Issue:3

    Topics: Administration, Oral; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combi

2006
Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Jun-01, Volume: 25, Issue:16

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Fluoroura

2007
Incidence and characteristics of peripheral neuropathy during oxaliplatin-based chemotherapy for metastatic colon cancer.
    Acta oncologica (Stockholm, Sweden), 2007, Volume: 46, Issue:8

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Colonic Neoplasms; Electrophys

2007
Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:5

    Topics: Adult; Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carci

2008
A phase I/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:5

    Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Breast Ne

2008
Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Apr-10, Volume: 26, Issue:11

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2008
Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Apr-10, Volume: 26, Issue:11

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2008
Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Apr-10, Volume: 26, Issue:11

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2008
Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Apr-10, Volume: 26, Issue:11

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2008
Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Apr-10, Volume: 26, Issue:11

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2008
Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Apr-10, Volume: 26, Issue:11

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2008
Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Apr-10, Volume: 26, Issue:11

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2008
Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Apr-10, Volume: 26, Issue:11

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2008
Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Apr-10, Volume: 26, Issue:11

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2008
Combined-modality therapy of esophageal cancer with radiotherapy, etanidazole, and cisplatin-fluorouracil, with or without surgery: neurotoxicity, other toxicities and outcome.
    International journal of radiation oncology, biology, physics, 1994, Jun-15, Volume: 29, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

1994
5-Fluorouracil-interferon-alpha 2b adjuvant treatment of Dukes C colorectal cancer.
    Diseases of the colon and rectum, 1994, Volume: 37, Issue:7

    Topics: Aged; Chemical and Drug Induced Liver Injury; Chemotherapy, Adjuvant; Colonic Neoplasms; Confidence

1994
Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. International Organization for Cancer Chronotherapy.
    Lancet (London, England), 1997, Sep-06, Volume: 350, Issue:9079

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chronotherapy; Colorectal Neoplasms; Fe

1997
Phase I and pharmacokinetic study of weekly 5-fluorouracil administered with granulocyte-macrophage colony-stimulating factor and high-dose leucovorin: a potential role for growth factor as mucosal protectant.
    Cancer investigation, 1999, Volume: 17, Issue:1

    Topics: Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Bone Marrow Diseases; Cohort Studies; Diarr

1999
Phase I study of a weekly schedule of oxaliplatin, high-dose leucovorin, and infusional fluorouracil in pretreated patients with advanced colorectal cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2001, Volume: 12, Issue:5

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diarrhea; Dose-Response

2001
Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2001, Volume: 12, Issue:9

    Topics: Administration, Oral; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combi

2001
Phase I trial of capecitabine in combination with interferon alpha in patients with metastatic renal cancer: toxicity and pharmacokinetics.
    Cancer chemotherapy and pharmacology, 2001, Volume: 48, Issue:6

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chr

2001
Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Jun-15, Volume: 20, Issue:12

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemot

2002
Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Jun-15, Volume: 20, Issue:12

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemot

2002
Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Jun-15, Volume: 20, Issue:12

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemot

2002
Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Jun-15, Volume: 20, Issue:12

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemot

2002
Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Jun-15, Volume: 20, Issue:12

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemot

2002
Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Jun-15, Volume: 20, Issue:12

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemot

2002
Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Jun-15, Volume: 20, Issue:12

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemot

2002
Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Jun-15, Volume: 20, Issue:12

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemot

2002
Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Jun-15, Volume: 20, Issue:12

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemot

2002
Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Jun-15, Volume: 20, Issue:12

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemot

2002
Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Jun-15, Volume: 20, Issue:12

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemot

2002
Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Jun-15, Volume: 20, Issue:12

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemot

2002
Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Jun-15, Volume: 20, Issue:12

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemot

2002
Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Jun-15, Volume: 20, Issue:12

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemot

2002
Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Jun-15, Volume: 20, Issue:12

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemot

2002
Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Jun-15, Volume: 20, Issue:12

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemot

2002
Phase II study of combination cytotoxic chemotherapy in advanced breast cancer: 2 years' followup.
    Cancer treatment reports, 1976, Volume: 60, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Dr

1976

Other Studies

61 other studies available for fluorouracil and Peripheral Nervous System Diseases

ArticleYear
Mirogabalin vs pregabalin for chemotherapy-induced peripheral neuropathy in pancreatic cancer patients.
    BMC cancer, 2021, Dec-09, Volume: 21, Issue:1

    Topics: Aged; Analgesics; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged Bic

2021
Incidence and risk factors associated with development of oxalipatin-induced acute peripheral neuropathy in colorectal cancer patients.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2023, Volume: 29, Issue:2

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorou

2023
Does statin suppress oxaliplatin-induced peripheral neuropathy in patients with colorectal cancer? A single-center observational study.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2023, Oct-28, Volume: 31, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neo

2023
Skin platinum deposition in colorectal cancer patients following oxaliplatin-based therapy.
    Cancer chemotherapy and pharmacology, 2019, Volume: 84, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Colorectal Neoplasms; Female; F

2019
Emotional distress and quality of life during folinic acid, fluorouracil, and oxaliplatin in colorectal cancer patients with and without chemotherapy-induced peripheral neuropathy: A cross-sectional study.
    Medicine, 2020, Volume: 99, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Cross-Sectional Studies; Femal

2020
Taxane-induced sensory peripheral neuropathy is associated with an SCN9A single nucleotide polymorphism in Japanese patients.
    BMC cancer, 2020, Apr-16, Volume: 20, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cy

2020
[Three Cases of Augmented Chemotherapy-Induced Peripheral Neuropathy after Changing from mFOLFOX6 to FOLFIRI Therapy in Patients with Colorectal Cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2020, Volume: 47, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Hu

2020
FLOX (5-fluorouracil + leucovorin + oxaliplatin) chemotherapy for colorectal cancer leads to long-term orofacial neurotoxicity: a STROBE-guided longitudinal prospective study.
    International journal of clinical oncology, 2020, Volume: 25, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms

2020
Comparison of FOLFIRINOX and Gemcitabine Plus Nab-paclitaxel for Treatment of Metastatic Pancreatic Cancer: Using Korean Pancreatic Cancer (K-PaC) Registry.
    American journal of clinical oncology, 2020, Volume: 43, Issue:9

    Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cross-

2020
Time-dependent discrepancies between physician-assessed and patient-reported oxaliplatin-induced peripheral neuropathy in patients with metastatic colorectal cancer who received mFOLFOX6 plus bevacizumab: a post hoc analysis (WJOG4407GSS2).
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2021, Volume: 29, Issue:7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Fema

2021
The updated five-year overall survival and long-term oxaliplatin-related neurotoxicity assessment of the FACOS study.
    Surgery today, 2021, Volume: 51, Issue:8

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Ad

2021
Effect of a Shortened Duration of FOLFOX Chemotherapy on the Survival Rate of Patients with Stage II and III Colon Cancer.
    Chemotherapy, 2018, Volume: 63, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Disease-Free Survival; Drug

2018
Prospective Study of the Clinical, Electrophysiologic, and Sonographic Characteristics of Oxaliplatin-Induced Neuropathy.
    Journal of neuroimaging : official journal of the American Society of Neuroimaging, 2019, Volume: 29, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Male; Middle Age

2019
Long-term neuropathy and quality of life in colorectal cancer patients treated with oxaliplatin containing adjuvant chemotherapy.
    Acta oncologica (Stockholm, Sweden), 2019, Volume: 58, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemother

2019
Effect of diabetes on neurological adverse effects and chemotherapy induced peripheral neuropathy in advanced colorectal cancer patients treated with different FOLFOX regimens.
    Pakistan journal of pharmaceutical sciences, 2019, Volume: 32, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva

2019
Optimal duration of adjuvant therapy for stage III colon cancer.
    Clinical advances in hematology & oncology : H&O, 2019, Volume: 17, Issue:5

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Capecitabine; Chem

2019
[A case with multiple liver metastases from rectal cancer responding completely to FOLFOX for a long duration without exacerbation of peripheral neuropathy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2013, Volume: 40, Issue:2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Fluorouracil; Humans; Leucovorin; Live

2013
Voltage-gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatin-induced peripheral neurotoxicity: results from a prospective multicenter study.
    Cancer, 2013, Oct-01, Volume: 119, Issue:19

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxyc

2013
Efficacy and tolerability of controlled-release oxycodone for oxaliplatin-induced peripheral neuropathy and the extension of FOLFOX therapy in advanced colorectal cancer patients.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2014, Volume: 22, Issue:6

    Topics: Aged; Analgesics, Opioid; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dela

2014
Incidence of cold-induced peripheral neuropathy and dose modification of adjuvant oxaliplatin-based chemotherapy for patients with colorectal cancer.
    Oncology, 2014, Volume: 87, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cold Temperatu

2014
Peripheral neuropathy in colorectal cancer survivors: the influence of oxaliplatin administration. Results from the population-based PROFILES registry.
    Acta oncologica (Stockholm, Sweden), 2015, Volume: 54, Issue:4

    Topics: Aged; Analysis of Variance; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; C

2015
A case of delayed oxaliplatin-induced pseudo-obstruction: an atypical presentation of oxaliplatin neurotoxicity.
    Acta clinica Belgica, 2015, Volume: 70, Issue:3

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colecto

2015
Long-term course of oxaliplatin-induced polyneuropathy: a prospective 2-year follow-up study.
    Journal of the peripheral nervous system : JPNS, 2014, Volume: 19, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Co

2014
Adjuvant Chemotherapy for Locally Advanced Rectal Cancer: Is It a Given?
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, Jun-10, Volume: 33, Issue:17

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant;

2015
Prevalence of Oxaliplatin-induced Chronic Neuropathy and Influencing Factors in Patients with Colorectal Cancer in Iran.
    Asian Pacific journal of cancer prevention : APJCP, 2015, Volume: 16, Issue:17

    Topics: Anemia; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Cape

2015
Large-scale prospective pharmacogenomics study of oxaliplatin-induced neuropathy in colon cancer patients enrolled in the JFMC41-1001-C2 (JOIN Trial).
    Annals of oncology : official journal of the European Society for Medical Oncology, 2016, Volume: 27, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplas

2016
Hyperacute peripheral neuropathy is a predictor of oxaliplatin-induced persistent peripheral neuropathy.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2017, Volume: 25, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Chronic Disease

2017
[Changes in peripheral neuropathy and platinum concentrations in patients undergoing surgery following modified FOLFOX6 therapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2008, Volume: 35, Issue:13

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Erythrocyte

2008
Unilateral taxane-induced onychopathy in a patient with a brain metastasis.
    Dermatology online journal, 2009, Mar-15, Volume: 15, Issue:3

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antine

2009
[Multicenter investigation of preventive measures against FOLFOX-induced neurotoxicity-a project of the 4th Chapter of the Oncology Research Group, Aichi Prefectural Society of Hospital Pharmacists].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2009, Volume: 36, Issue:8

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco

2009
[Revision of the informed consent form for patients based on investigation of adverse events of mFOLFOX6 regimen].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2009, Volume: 36, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol

2009
Capecitabine combined with oxaliplatin (CapOx) in clinical practice: how significant is peripheral neuropathy?
    Annals of oncology : official journal of the European Society for Medical Oncology, 2010, Volume: 21, Issue:8

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Fluorourac

2010
New recommendation of doses in an ongoing phase II study of docetaxel, oxaliplatin and capecitabine as first line therapy in advanced gastro-oesophageal cancer.
    Acta oncologica (Stockholm, Sweden), 2011, Volume: 50, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase II as Topic; De

2011
Associations between oxaliplatin-induced peripheral neuropathy and polymorphisms of the ERCC1 and GSTP1 genes.
    International journal of clinical pharmacology and therapeutics, 2010, Volume: 48, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asian People; DNA-Bi

2010
Capecitabine combined with oxaliplatin (CAPOX) in clinical practice: how significant is peripheral neuropathy?
    Annals of oncology : official journal of the European Society for Medical Oncology, 2011, Volume: 22, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Fluorouracil; Humans; O

2011
[PSK decreased FOLFOX4-induced peripheral neuropathy and bone marrow suppression in patients with metastatic colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2011, Volume: 38, Issue:5

    Topics: Agaricales; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Co

2011
Development of a standardized method for contouring the lumbosacral plexus: a preliminary dosimetric analysis of this organ at risk among 15 patients treated with intensity-modulated radiotherapy for lower gastrointestinal cancers and the incidence of rad
    International journal of radiation oncology, biology, physics, 2012, Oct-01, Volume: 84, Issue:2

    Topics: Anatomic Landmarks; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Fluorouracil; Hu

2012
Ixabepilone-associated peripheral neuropathy: data from across the phase II and III clinical trials.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2012, Volume: 20, Issue:11

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Tria

2012
Predicting acute and persistent neuropathy associated with oxaliplatin.
    American journal of clinical oncology, 2013, Volume: 36, Issue:4

    Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chronic Disease; Cohort

2013
Identification of clinical predictive factors of oxaliplatin-induced chronic peripheral neuropathy in colorectal cancer patients treated with adjuvant Folfox IV.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2013, Volume: 21, Issue:5

    Topics: Age Factors; Aged; Alcohol Drinking; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, A

2013
Calcium channel blockers reduce oxaliplatin-induced acute neuropathy: a retrospective study of 69 male patients receiving modified FOLFOX6 therapy.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2013, Volume: 67, Issue:1

    Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Calci

2013
Effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity.
    Oncology (Williston Park, N.Y.), 2002, Volume: 16, Issue:12 Suppl N

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Capecitabine; Celecoxib; Colorectal Neoplasms;

2002
Primary chemoradiation as definitive treatment for unresectable cancer of the trachea.
    Canadian respiratory journal, 2003, Volume: 10, Issue:3

    Topics: Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy

2003
Short-time infusion of oxaliplatin (Eloxatin) in combination with capecitabine (Xeloda) in patients with advanced colorectal cancer.
    Acta oncologica (Stockholm, Sweden), 2003, Volume: 42, Issue:8

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; C

2003
Peripheral neuropathy associated with capecitabine.
    Anti-cancer drugs, 2004, Volume: 15, Issue:8

    Topics: Capecitabine; Clinical Trials, Phase II as Topic; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP);

2004
Leflunomide and peripheral neuropathy: a potential interaction between uracil/tegafur and leflunomide.
    Clinical pharmacology and therapeutics, 2005, Volume: 78, Issue:1

    Topics: Administration, Oral; Aged; Arthritis, Rheumatoid; Comorbidity; Disease Progression; Drug Administra

2005
Preoperative chemoradiation for rectal cancer causes prolonged pudendal nerve terminal motor latency.
    Diseases of the colon and rectum, 2006, Volume: 49, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Biopsy; Female; Fluorouracil; Follow-U

2006
Peripheral neuropathy exacerbation associated with topical 5-fluorouracil.
    Anti-cancer drugs, 2006, Volume: 17, Issue:9

    Topics: Aged; Antimetabolites, Antineoplastic; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Deh

2006
[Reduction of oxaliplatin-related neurotoxicity by calcium and magnesium infusions].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:4

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Calcium; Colorectal Neoplas

2007
A case of 5-fluorouracil-induced peripheral neuropathy.
    Clinical toxicology (Philadelphia, Pa.), 2008, Volume: 46, Issue:3

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Electromyography; Female; Fluorouracil; Humans; Low

2008
[Reduction of oxaliplatin-related neurotoxicity by Gosha-jinki-gan].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2008, Volume: 35, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol

2008
Sequential methotrexate and 5-fluorouracil: improved response rate in metastatic colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1984, Volume: 2, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Colonic Neoplasms; Drug

1984
Locally advanced primary colorectal cancer: intraoperative electron and external beam irradiation +/- 5-FU.
    International journal of radiation oncology, biology, physics, 1997, Feb-01, Volume: 37, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colonic Neoplasms; Combined Modalit

1997
Peripheral neuropathy associated with weekly oral 5-fluorouracil, leucovorin and eniluracil.
    Anti-cancer drugs, 2001, Volume: 12, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain; Colonic Neoplasms; Dihydrouracil

2001
[Prevention of oxaliplatin-induced neuropathy by carbamazepine. A pilot study].
    Deutsche medizinische Wochenschrift (1946), 2002, Jan-18, Volume: 127, Issue:3

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco

2002
Acute oxaliplatin-induced peripheral nerve hyperexcitability.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Apr-01, Volume: 20, Issue:7

    Topics: Acute Disease; Aged; Anticonvulsants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Pr

2002
Orofacial complications of chemotherapy for breast cancer.
    Oral surgery, oral medicine, and oral pathology, 1992, Volume: 74, Issue:2

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Candidiasis, Oral; Chi-Squa

1992
Low prevalence of cisplatin-induced neuropathy after 4-day continuous infusion in head and neck cancer.
    Cancer, 1990, Jun-15, Volume: 65, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; El

1990
Doxifluridine (5'-dFUrd) in patients with advanced colorectal carcinoma. A phase II study.
    Cancer chemotherapy and pharmacology, 1985, Volume: 15, Issue:2

    Topics: Angina Pectoris; Brain Diseases; Carcinoembryonic Antigen; Colonic Neoplasms; Drug Evaluation; Elect

1985
High-dose cisplatin administration without hypertonic saline: observation of disabling neurotoxicity.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1985, Volume: 3, Issue:10

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Carcinoma, Squamo

1985
Palliation of pelvic recurrence of colorectal cancer with intra-arterial 5-fluorouracil and mitomycin.
    Cancer, 1985, Nov-01, Volume: 56, Issue:9

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; C

1985
chemdatabank.com